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Abstract
PARP10 belongs to the poly-ADP-ribose polymerase family of ADP-ribosylating en-
zymes and was originally found to interact with MYC. ADP-ribosylation controls
many cellular processes, including transcription, DNA repair, and bacterial toxic-
ity. It has been shown recently that PARP10 differs from the bona fide PARP en-
zymes because it lacks polymerase activity and instead functions as mono-ADP-
ribosyltransferase. This difference can be explained by the lack of a catalytic gluta-
mate in the active center that is also lacking in the majority of the other PARP family
members. Therefore PARP10 is a prototype of a novel subclass of PARPs restricted
to mono-ADP-ribosylation. So far only little is known about PARP10’s physiological
function. New experimental methods would expand the attempts to gain insight into
the biology of PARP10.
As one instrument siRNA-resistant wildtype PARP10 expression vectors have been
designed. Using siRNA-resistant vectors allows analyzing the effects of mutants with
and without the presence of endogenous proteins.
In the attempts of purifying a ADP-ribosylated peptide containing an automodifi-
cation site of PARP10 for immunization purposes, we tried different approaches to
define the suitability of the peptide as PARP10 substrate. However, no clear evi-
dence was obtained to suggest that this peptide was ADP-ribosylated sufficiently by
PARP10. It is possible that the interaction with the catalytic site of PARP10 requires
proper three-dimensional folding of the substrate.
A further approach to elucidate physiological functions of PARP10 is to identify new
substrates and interaction partners. The method of choice was a state-of-the-art pro-
tein array, which allows the identification of potential PARP10 substrates within a
large subset of the human proteome. To perform such assays, several questions
had to be evaluated and answered: Does PARP10 recognise and modify substrates
while bound to a support, i.e. in a solid phase approach? Which are the best de-
tection method and the optimal reaction condition to determine ADP-ribosylation?
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Conditions could be established that allowed modification of known substrates im-
mobilized on nitrocellulose supports by PARP10. Moreover more than 40 proteins
were identified in the KSI Protoarray containing a total of more than 8,000 full-
length human proteins. These potential substrates will have to be confirmed by in-
solution PARP assays and validated in cells before proposing new hypothesises about
PARP10’s physiological function and its cellular relevance.
Apart from finding formerly unknown hypothetical substrates of PARP10, a high-
troughput screening could be established to study ADP-ribosylation reactions. Af-
ter studying other PARP family members, the establishment of an ADP-ribosylome
seems reasonable.
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Zusammenfassung
PARP10 gehört zur Familie der Poly-ADP-Polymerasen, die ADP-Ribosylierung ver-
mitteln und wurde ursprünglich als Interaktionspartner von MYC entdeckt. ADP-
Ribosylierung kontrolliert viele zelluläre Prozesse, wie Transkription und DNA-
Reparatur und vermittelt außerdem die Toxizität einiger bakterieller Toxine. Kür-
zlich konnte gezeigt werden, dass sich PARP10 hinsichtlich des enzymatischen Mech-
anismuses von den bisher erforschten PARP-Enzymen unterscheidet und anstelle der
Poly-ADP-Ribosylierung lediglich Mono-ADP-Ribosylierung vermittelt. Dieser Un-
terschied ergibt sich wahrscheinlich aus dem Fehlen des katalytischen Glutamates
im aktiven Zentrum des Enzyms, das in der Mehrheit der PARPs fehlt. Daher hal-
ten wir PARP10 für den Prototyp einer neuen Unterklasse von PARPs mit Mono-
ADP-Ribosylierungs-Aktivität. Da bisher wenig über die physiologische Funktion
von PARP10 bekannt ist, würde eine Erweiterung des verfügbaren Methodenspek-
trums die Forschungsanstrengungen stärken.
Als ein Instrument wurden siRNA-resistente Wildtyp PARP10 Expressionsvektoren
designed. Mit siRNA-resistenten Vektoren ist es möglich, den Effekt von Enzymmu-
tanten in als auch ohne Gegenwart von endogenen Proteinen zu analysieren.
Mit verschiedenen Ansätzen versuchten wir zu bestätigen, ob ein Peptid, das eine
Automodifizierungsstelle von PARP10 enthält, PARP10 als Substrat dient. Ein
solches modifiziertes und aufgereinigtes Peptid könnte für Immunisierungen genutzt
werden. Es konnte nicht mit Sicherheit nachgewiesen werden, dass eine ADP-
Ribosylierung erfolgt. Möglicherweise entsprach das Peptid nicht der erforderlichen
Tertiärstruktur, um als Substrat erkannt zu werden.
Um die physiologische Funktion von PARP10 zu erhellen, bietet es sich an, neue Sub-
strate und Interaktionspartner herauszufinden. Die Methode der Wahl ist ein Protein
Array, der die Identifizierung von potentiellen PARP10 Substraten aus einer großen
Gruppe an humanen Proteinen erlaubt. Um solche Protein Arrays durchzuführen,
musste bestätigt werden, dass PARP10 seine Substrate auch in gebundenem Zustand,
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wie es in Festphase-Assays der Fall ist, erkennt und modifiziert. Außerdem mussten
optimale Reaktions- und Detektionsbedingungen gefunden werden.
Es konnten Bedingungen gefunden werden, unter denen bereits bekannte, auf Nitro-
celluloseoberflächen immobilisierte PARP10-Substrate von PARP10 modifiziert wur-
den. Der Protein Array, der 8.000 humanen Full-length Proteine enthält, enthüllte
mehr als 40 potentielle PAPR10-Substrate. Diese müssen in PARP-Assays in Lösung
bestätigt und in Zellkulturexperimenten validiert werden, bevor neue Hypothesen
über PARP10 aufgestellt werden können.
Neben der Identifizierung bisher unbekannter hypothetischer PARP10-
Substrate, kann diese Hochdurchsatzmethode die Forschung zu ADP-
Ribosylierungsreaktionen neu definieren und erweitern. Nach Anwendung des
Protein Arrays bei weiteren PARP Mitgliedern scheint es möglich, ein ADP-
Ribosylom zu etablieren, das alle Proteine enthält, die ADP-ribosyliert werden.
iv
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1 Introduction
1.1 Physiological relevance of ADP-ribosylation
Poly(ADP-ribose) is a homo polymer that consists of adenosine diphosphate (ADP)-
ribose units. It is synthesized by the poly(ADP-ribose) polymerase (PARP) from
nicotinamide adenine dinucleotide (NAD), which is hydrolyzed to nicotinamide and
ADP-ribose (Reeder et al., 1967). NAD is an important coenzyme in several redox
reactions (Schreiber et al., 2006).
PARPs mediate the covalent binding of ADP-ribose to the γ-carboxyl group of glu-
tamates and aspartates of the acceptor proteins (Burzio et al., 1979); (Riquelme et al.,
1979). The single ADP-ribose units are linked by an α-1”→2’ glycosidic bond in the
linear part of the polymer. The linkage in the branching regions is commonly de-
scribed as Ado (P)-Rib (P)-Rip-P binding containig a creating ribose 1”’→2” ribose
linkage (Miwa et al., 1981). For further information see also figure 1.1. More than
200 ADP-ribose units can be linked in chains with branched side chains (Kanai et al.,
1978).
Long poly(ADP-ribose) chains arrange into helical structures similar to nucleic acids
(Minaga and Kun, 1983). This fact explains cross reactivity of antibodies against DNA
and RNA with poly(ADP-ribose) (Sibley et al., 1986).
Poly(ADP-ribose) is formed in three steps, all three functions can be executed
by PARP1 (D’Amours et al., 1999). The first step is the initiation which means
mono(ADP-ribosyl)ation of the substrate, followed by elongation of the polymer as
the second step and in a third step the completion by the branching reaction. The
degradation of poly(ADP-ribose) also requires three steps. Exoglycosidic and endo-
glycosidic activity is carried out by poly(ADP-ribose) glycohydrolase (PARG) (Ike-
jima and Gill, 1988); the last ADP-ribose is proposed to be removed from the substrate
by ADP-ribose proteinlyase, a hypothetical enzyme which has neither been charac-
terized nor cloned yet (Oka et al., 1984).
1
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Figure 1.1 – Poly(ADP-ribose) Structure
Poly(ADP-ribose) polymerases (PARPs) cleave the glycosidic bond of NAD+ between
nicotinamide and ribose followed by the covalent modification of mainly glutamate
residues of acceptor proteins with an ADP-ribosyl unit. PARPs also catalyse an adduct
elongation, giving rise to linear polymers with chain lengths of up to about 200 ADP-
ribosyl units, characterized by their unique ribose (1”→2’) ribose phosphate- phos-
phate backbone. At least some of the PARP family members also catalyse a branching
reaction by creating ribose (1”’→2”) ribose linkages. The sites of hydrolysis catalysed
by poly(ADP-ribose) glycohydrolase (PARG), the major poly(ADPribose)-degrading
enzyme, are indicated by arrows. Figure from (Bürkle, 2005).
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Another group of enzymes involved in poly(ADP-ribose) catabolism are ADP-ribose
hydrolases. Three different ADP-ribose hydrolases (ARH1-3) have been identified in
humans so far. ARH1 specifically hydrolyzes ADP-ribosylarginine. While there is
only little known about ARH2, ARH3 exhibits PARG activity, generating ADP-ribose
from poly(ADP-ribose), but does not hydrolyze ADP-ribosylarginine, -cysteine, -
diphthamide, or -asparagine bonds (Oka et al., 2006).
Poly(ADP-ribose) metabolism and NAD metabolism are closely connected to each
other because NAD serves as the cosubstrate for PARP-mediated reactions, thus
PARPs are involved in regulating NAD levels in cells (Wielckens et al., 1983). In
conditions of massive DNA damage, excessive poly(ADP-ribose) synthesis can cause
a rapid depletion of cellular NAD pools and impairment of NAD-dependent cellular
functions, including glycolysis and mitochondrial respiration. Trying to reconstitute
NAD levels, cells deplete their ATP pools, thereby creating an insurmountable energy
shortage leading to necrotic cell death (Rouleau et al., 2004). During low-to-moderate
levels of DNA damage, PARP1 activation causes rapid auto-poly(ADP-ribosyl)ation
as well as covalent modification of histones and macrodomain proteins inducing the
repair of the damaged site by base excision repair (BER) (Rouleau et al., 2004).
In-vitro studies revealed several proteins to become poly(ADP-ribosyl)ated. Some
prominent examples are the nuclear substrates p53, FOS, core histones as well as his-
tone H1, RNA- and DNA polymerases, DNA ligases and topoisomerases (D’Amours
et al., 1999).
There are several scenarios how poly(ADP-ribosyl)ation might cause its effects, e.g.
the localized relaxation of chromatin at the site of DNA damage (Poirier et al., 1982),
mediated either by direct modification of histones or noncovalent interaction of hi-
stones with poly(ADP-ribose) present as automodification on PARP1 or -2; a dam-
age signalling function (Pleschke et al., 2000); or the recruitment of specific DNA
repair proteins to the site of damage via noncovalent interaction with poly(ADP-
ribose) (Bürkle, 2005).
3
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1.2 The PARP Family
The poly(ADP-ribose) polymerases are responsible for the intracellular poly(ADP-
ribose) anabolism. It is a heterogenous group consisting of 17 members which can
be subdivided into three groups as proposed by Kleine et al. (Kleine et al., 2008) and
briefly specified below. PARPs can only be found in higher and a few lower eu-
karyotes but they are absent in yeast (Otto et al., 2005). Interestingly, evidence for
poly(ADP-ribosyl)ation has recently been found in archaebacteria (Castellano et al.,
2009). PARPs combine their catalytic domains with a variety of adapter domains
such as zinc fingers, SAM, Ankyrin, BRCA1 C-terminal (BRCT) motifs and macro do-
mains. The diversity of domains associated with the PARP catalytic domain, which
is also depicted in figure 1.2, implicates functions in many biological processes.
1.2.1 PARP Family Group I
The first group consists of PARP1-5, likely possesses poly(ADP-ribosyl)ation capacity
and is characterized by the amino acid triad histidine, tyrosine and glutamate (HYE)
in the active center. Poly(ADP-ribosyl)ation capacity has not been demonstrated for
all members yet.
1.2.1.1 PARP1
Poly(ADP-ribose) polymerase 1 is the founding member of the PARP family. It is
literally named molecular sensor of DNA breaks but apart from this PARP1’s function
includes a role in immune and inflammatory response as well as in cell proliferation
and differentation (Hakme et al., 2008).
The human gene of the 1,014 amino acids (aa) long enzyme resides on chromosome
1q41-42 (Ame et al., 2004). PARP1 uses NAD+ as a coenzyme to catalyze the covalent
attachment of ADP-ribose units onto the γ-carboxyl group of glutamate residues of
acceptor proteins which are often associated with DNA transactions (heteromodifica-
tion). The enzyme also features automodification capacitiy (Schreiber et al., 2006).
PARP1 contains several different domains. There is a DNA-binding domain, includ-
ing two zinc fingers (aa 12-90 and aa 116-200) responsible for the interaction with
DNA breaks, next there is a nuclear localization sequence (NLS), accounting for nu-
clear uptake of PARP1. Furthermore a BRCT motif could be identified (aa 387-461),
4
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Figure 1.2 – Domain architecture of the human PARP family members
Within each putative PARP domain, the region which is homologous to residue 859-908
of PARP1 - the PARP signature - is indicated in darker color. BRCT, SAM, IUM, MVP-
BD, VWA and ANK are protein interaction modules. ANK ankyrin; BRCT BRCA1-
carboxy-terminus; HPS homopolymeric runs of His, Pro, and Ser; macro domain in-
volved in ADP-ribose and poly(ADP-ribose) binding; MVP-BD MVP-binding, NES nu-
clear export sequence, N(o)LS nulear (nucleolar) localization signal; PARP poly(ADP-
ribose) polymerasePARP_Reg putative regulatory domain: RRM RNA-binding motif;
SAM sterile α-motif; TiPARP 2,3,7,8-tetrachlorodibenzo-p-dioxin-inducible poly(ADP-
ribose) polymerase; UIM ubiquitin interaction motif, VIT vault inter-α-trypsin; vPARP
vault poly(ADP-ribose) polymerase, vWA von Willebrand factor type A; WGR con-
served W, G and R residues; WWE conserved W, W and E residues; ZnF DNA or
RNA binding zinc fingers, except PARP1 ZnFIII, which coordinates DNA-dependent
enzyme activation. Figure from (Hakme et al., 2008).
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which is found whithin many DNA damage repair and cell cycle checkpoint pro-
teins (Marchler-Bauer et al., 2009). Between aa 543-645 there is the WGR PARP1 like
region, which has been named after the most conserved central motif of the domain
and typically occurs together with a catalytic PARP domain. It has been proposed to
function as a nucleic acid binding domain (Marchler-Bauer et al., 2009). The PARP
like domain (aa 662-997) displays catalytic activity hosting the catalytic E988 respon-
sible for poly(ADP-ribosyl)ation capacity. The active site is formed by a phylogenet-
ically well-conserved sequence of about 50 residues (aa 859-908 of hPARP1). This
”PARP signature” contains the NAD acceptor sites and critical residues involved in
the initiation, elongation and branching of poly(ADP-ribosyl)ation (Altmeyer et al.,
2009). This signature was used to search protein databases extending the group to 17
family members (Ame et al., 2004).
Recently an additional zinc finger module was identified (aa 216-266). The new zinc
binding domain is not essential for the DNA binding activity, it is probably involved
in protein-protein interactions that orchestrate PARP1 activation and is critical to the
DNA-dependent stimulation of PARP1. (Langelier et al., 2008).
DNA single and double strand breaks (SSBs and DSBs) highly stimulate PARP1 en-
zyme activity and rises the level of poly(ADP-ribose) up to 500 fold compared to
unstimulated cells. DNA lesions also stimulate PARG, which results in a half life of
pADPr of less than a minute. Damage-induced pADP-ribosylation of H1 and H2B
contributes to the relaxation of the 30nm chromatin fiber in vitro. This immediate
conformational change of the nucleosomal superstructure most likely triggers the ac-
cess of repair enzymes to the lesion (Oliver et al., 2004), which is crucial for the dam-
aged site to be repaired by base excision repair (BER), underlining the role of pADP-
ribosylation in local chromatin remodeling, protection of DNA breaks, recruitment
and modulation of the activity of repair factors (Rouleau et al., 2004).
D’Amours et. al. describe how PARP1 is thought to mediate DNA repair (D’Amours
et al., 1999). As soon as DNA damage occurs, PARP1 senses the DNA break by its
zinc fingers, becomes activated and ADP-ribosylates itself and histones, whith H1 as
the major acceptor (Poirier et al., 1982). Enzyme and DNA become gradually more
charged, an electrorepulsive gradient is established and cumulates in the repulsion of
PARP1 from the site of DNA lesion (Ferro and Olivera, 1982). The automodification
of PARP1 leads to an inhibition of enzyme activity and reduces its affinity for DNA.
Meanwhile, pADPr recruits XRCC, the SSBR/BER scaffold protein and initiates DNA
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repair (Schreiber et al., 2006). The poly-ADP-ribosylated PARP1 is freed from nega-
tive charge by PARG which also restores enzyme activity and DNA affinity, allowing
PARP1 to enter the cycle again. The lack of dynamic recruitment of XRCC1 in PARP1
deficient cells leads to an important delay in strand-break rejoining causing severe
DNA repair defects (Trucco et al., 1998).
PARP1 is not only involved in DNA repair but also in the inflammatory response. It is
involved in the activation of NFκB and synthesis of proinflammatory factors (Hassa
and Hottiger, 1999). The sensitivity of cells, in particular endothelial cells, to oxygen
radicals produced during inflammation with consequences on DNA damage, energy
depletion and cell death is increased, possibly triggered by the release of apoptosis-
inducing factor (AIF) (Yu et al., 2002). AIF is involved in neuronal as well as my-
ocardial cell death by ischemia-reperfusion lesions in which PARP1 plays a critical
role (Kim et al., 2003).
1.2.1.2 Clinical application of PARP1 inhibitors
PARP inhibitors were originally discovered by an empirical, high throughput screen-
ing followed by optimization modeling on a structure-based design (Jagtap et al.,
2005). First inhibitors were developed 30 years ago, e.g. nicotinamide and 3-
aminobenzamide which were competitive inhibitors that lacked specificity and po-
tency (Peralta-Leal et al., 2009).
The benzamides inhibit PARP by interfering with the binding of NAD to the en-
zyme’s active site. Unfortunately benzamide also binds to DNA, thereby preventing
the recognition of DNA breaks by PARP1 and also inhibiting PARP enzyme activa-
tion (Southan and Szabo, 2003). The more recently developed PARP inhibitors con-
tain an aromatic ring, which contributes to PARP inhibition and they all interfere with
the reaction between PARP and NAD+. These drugs tend to have a short half-life and
require frequent re-application in patients (Peralta-Leal et al., 2009). Structural infor-
mation on selected PARP inhibitors is given in figure 1.3.
PARP inhibitors have been shown to enhance significantly the toxicity of several ther-
apies that target DNA damage (Jagtap et al., 2005). Consequently, pharmacological
inhibitors of PARP have the potential to enhance the cytotoxicity of certain DNA-
damaging anti-cancer drugs. They reduce parenchymal cell necrosis, for example in
myocardial infarction or stroke, and down-regulate multiple simultaneous pathways
7
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Figure 1.3 – Inhibitors of PARP1 The classical inhibitors are nicotinamide, benzamide
and substituted benzamide, in particular 3-aminobenzamide. Important inhibitors in
clinical trials include ABT-888 and AG014699. See table Inhibitors of PARP1 for further
information. Figure from (Peralta-Leal et al., 2009).
of tissue injury and inflammation, e.g. in colitis, circulatory shock or diabetic compli-
cations (Jagtap et al., 2005). Preclinical trials suggest therapeutical activity in nearly
every human organ (Jagtap et al., 2005); in the brain for instance, PARP inhibitors
shall improve neurological status in patients suffering from stroke, parkinson’s dis-
ease or hypoglycemia. They might improve myocardial contractility of the heart mus-
cle during myocardial infarction, transplantation and ischemic or aging-associated
heart failure. Additional application fields could be the vasculature system, the lung,
the endocrine pancreas, GI tract, joints, skeletal muscle, kidney, liver, eye, ear, skin,
peripheral nerves and systemic septic shock. PARP inhibitors might even cure erectile
dysfunction (Jagtap et al., 2005).
Whilst many of these ideas are far away from being used in patients routinely, PARP
inhibitors have already shown to improve the effectiveness of the treatment of colon
carcinoma, glioblastoma and non-small cell lung cancer (Haince et al., 2005).
The most prominent application is the use of PARP inhibitors in hereditary breast
cancer with mutation in the BRCA1/2 genes (Wooster and Weber, 2003). Fong et.
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al. showed in their phase I trial that the PARP inhibitors Olaparib (KU59436) was
effective concerning antitumor activity and PARP inhibition while producing few ad-
verse effects (Fong et al., 2009). BRCA1/2 are important for DNA double strand break
repair by homologous recombination (Tutt and Ashworth, 2002). These cells show ex-
treme sensitivity to PARP inhibitors (Bryant et al., 2005) which Farmer et al. (Farmer
et al., 2005) try to explain with the following model: PARP inhibition leads to per-
sistent single strand gaps in the DNA. If these gaps are encountered by a replication
fork, the single strand gaps may degenerate into DSBs in cells deficient in DNA repair.
Normally, these DSBs can be repaired by RAD51-dependent homologous recombina-
tion, a process which involves BRCA1 and 2. In the absence of BRCA1 und 2, the
replication fork cannot restart and collapses, which results in persistent chromatid
breaks.
The repair of these breaks by alternative error-prone DSB repair mechanisms such as
non-homologous end joining (NHEJ) or single-strand annealing cause a large num-
ber of chromatid breaks and aberrations, leading to a loss of viability. Recently, two
groups showed the acquisition of resistance to PARP inhibitors by a secondary muta-
tion which restored the open reading frame (ORF) of BRCA2 (Sakai et al., 2008), (Ed-
wards et al., 2008). The mutations possibly arise from error-prone repair caused by
initial BRCA2 deficiency.
There are at least five PARP inhibitors in clinical trial development (Peralta-Leal et al.,
2009), summarized in table Inhibitors of PARP1. Most of them are in phase I clinical
trials which is the first stage of testing drugs in humans supposed to discover toxicity.
Some PARP inhibitors have even completed phase II, which intends to explore dosage
finding and drug efficacy. Phase III trials are the most time-consuming and expensive.
They assess the drug’s effectivity in comparison with current gold standard treatment.
Phase IV is also known as Post Marketing Surveillance Study while the drug is used
in the treatment of patients, but keeps being monitored to detect formerly unknown
side effects.
1.2.1.3 PARP2, 3, 4, 5
The second member of the human PARP family is a 64 kDa enzyme of 570 aa length.
The corresponding gene resides on chromosome 14q11.2 (Ame et al., 2004). PARP1
and PARP2 have structural homology with the active site of the bacterial ADP-
ribosylating toxin from Clostridium diphtheria (Ruf et al., 1996). The PARP1 and PARP2
9
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Agent Company Single/
Combination
Therapy
Disease Clinical
Status
AG014699 Pfizer, USA Single agent/
combination
with
Temozolomide
Locally advanced or metastatic
breast cancer and advanced
ovarian cancers in known
carriers of a BRCA1 or BRCA2
mutation; malignant melanoma
Phase I in
solid tumors
completed,
phase II in
melanoma
complete
KU59436
Olaparib
Astra
Zeneca/
KuDOS,
UK
Single Advanced solid tumors Phase I
Women with advanced breast
cancer
Phase II
Measurable BRCA1- or
BRCA2-positive advanced
ovarian cancer
Phase II
ABT-888 Abbott
Laborato-
ries
USA
Single Refractory solid tumors and
lymphoid malignancies
Phase 0
ongoing
BSI-201 BiPar, USA Single Advanced solid tumors
(ovarian, uterine, lung and
other)
Phase I
completed,
Phase II
ongoing
INO-
1001
Inotek/
Genentech,
USA
In combination
with
Temozolomide
or single
Metastatic melanoma,
glioblastoma
Phase I
Combination
with
Doxorubicin
P53 deficient breast cancer precinical
Single Cardiovascular indications:
Prevention of postoperative
aortic aneurysm repair
complications
Phase II
GPI21016 MGI
Pharma
Combination
with
Temozolimide
Solid tumors Phase I
planned
Table 1.1 – Inhibitors of PARP1
Table adapted from (Peralta-Leal et al., 2009).
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crystal structures differ only in the vicinity of the acceptor site, which most likely re-
flects differences in substrate preferences (Oliver et al., 2004). The high level of struc-
tural homology is also reflected in their functions: PARP1 and PARP2 heterodimerize
and appear to function at least in part redundantly.
The PARP2 catalytic activity is activated by DNA strand breaks but shows reduced
capacity to synthesize APD-ribose polymers in comparison to PARP1. Mice that lack
Parp1 show hardly any phenotype because Parp2 is able to compensate Parp1’s func-
tion (Wang et al., 1995), a phenomenon which led to the discovery of Parp2 as a result
of the presence of residual DNA-dependent Parp activity in embryonic fibroblasts
derived from Parp1-deficient mice (Ame et al., 1999).
Parp1/Parp2 double gene disruption results in embryonic lethality: mice die at the
onset of gastrulation, which Menessier et al. interpret as the demonstration that
DNA-dependent poly(ADP-ribosyl)ation is essential during early embryogenesis
(Menissier de Murcia et al., 2003). Nevertheless the embryonic lethality does not
have to be DNA-dependent. It could rely on other yet unknown functions of PARP
enzyme not necessarily requiring enzyme activity.
PARP1 and PARP2 share common interaction partners involved in Single Strand
Break Repair (SSBR) and Base Excision Repair (BER) pathways: XRCC1, DNA-
polymerase β, DNA ligase III (Ame et al., 2004). Although most functions of
PARP2 remain unclear there are hints for its participation in telomere integrity con-
trol (Dantzer et al., 2004).
PARP3 is a 60 kDa enzyme of 533 aa length. The gene locus resides on chromosome
3p21. It was identified as a core component of the centrosome preferentially located at
the daughter centriole (Augustin et al., 2003). PARP3 interacts with PARP1 which in
part also resides at the centrosome, suggesting a link between DNA damage surveil-
lance network and the mitotic fidelity checkpoint (Kanai et al., 2003).
vPARP is synonymous of PARP4, the largest protein of the family (192.6 kDa) with
1724 aa. It’s gene is coded on chromosome 13q11. This protein has a catalytic
domain which is homologous to that of poly(ADP-ribosyl) transferase, but lacks
an N-terminal DNA binding domain which activates the C-terminal catalytic do-
main of poly(ADP-ribosyl) transferase. vPARP is not capable to bind to DNA di-
rectly. It is associated with vault particles, a cytoplasmic ribonucleoprotein complex
that associates two other highly conserved proteins, major vault protein (MVP) and
telomerase-associated protein (TEP1) and untranslated vault RNA (vRNA) (Kickhoe-
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fer et al., 1999). The Kickhoefer group found an increased susceptibility of vault
poly(ADP-ribose) polymerase-deficient mice to carcinogen-induced tumorigenesis
(Raval-Fernandes et al., 2005).
Tankyrase is an acronym for TRF1-interacting, ankyrin-related ADP-ribose poly-
merase. Two different enzymes are described (tankyrase1, -2 = PARP5a, -5b).
Tankyrase1 has been discovered in a two hybrid screen as a factor which regulates
telomere homeostasis by modifying the negative regulator of telomere length (TRF1)
(Smith et al., 1998), (Ame et al., 2004). The knock-down of tankyrase1 gene expres-
sion with siRNA reveals an essential role of the protein in mitotic segregation (Dynek
and Smith, 2004), while overexpression of tankyrase1 promotes ADP-ribosylation of
TRF1, leading to its release from telomeres and to telomere elongation after which
tankyrase is finally ubiquinated and degraded by the proteasome (Chang et al., 2003).
Tankyrase1 might be an important insulin signaling target (Chi and Lodish, 2000).
Tankyrase2 or PARP5b exhibits > 85% sequence identity with Tankyrase1 and medi-
ates probably overlapping functions in telomere homeostasis and vesicle trafficking
(Sbodio et al., 2002). When overexpressed, Tankyrase2 induces caspase-independent
cell death through the loss of mitochondrial potential (Kaminker et al., 2001).
1.2.2 PARP Family Group II
The second group of the PARP family consisting of PARP6-8, 10-12 and 14-16 is
not as well characterized as the first group. They all lack the catalytic glutamate
residue equivalent to E988 in PARP1 which might limit their enzymatic activity to
mono(ADP-ribosyl)ation (Ame et al., 2004); (Till et al., 2008) (Kleine et al., 2008).
This fact does not reduce the impact of this enzyme subgroup because the first ADP-
ribose synthesized onto a substrate is the rate limiting step for the polymerization
and branching reaction. Therefore the biological importance of these PARPs lacking
the glutamate catalytic residue should not be neglected (Ame et al., 2004).
For most members few information is available. TiPARP, PARP12 and -13 are sub-
grouped to CCCH-type zinc finger PARPs because they all contain CX8CX5CX3-like
zinc fingers (Schreiber et al., 2006).
TiPARP is a synonym for PARP7 that was found in a TCDD-induced mRNA differen-
tial expression display. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) modulates gene
12
1.2. The PARP Family
expression thereby creating pleotropic effects in mammalian species. TiPARP, consist-
ing of 657 aa residues with about 75 kDa, exhibits PARP activity towards histones (Ma
et al., 2001). Ma et al. found a strong homology to RM1 which is induced during long-
term potentiation, a memory formation process, and to TIL which is induced in T cells
infiltrating progressing tumors. (Ma et al., 2001).
PARP9, -14, -15 are the macro PARPs. Another description is B aggressive lymphoma
proteins (BAL1, 2a/2b, 3, or PARP9, PARP14, and PARP15). Macro domains are
thougt to be high-affinity ADP-ribose binding modules with a conserved binding
pocket in the macro domain fold that recognizes poly ADP-ribose as a ligand (Kar-
ras et al., 2005). PARP14 could be characterized comprising mono(ADP-ribosyl)ation
capacity (Kleine et al., 2008).
In PARP7, -11, -12, -13, -14 a WWE domain is remarkable as it usually occurs in classes
of proteins associated with ubiquination (Aravind, 2001).
Although mentioned here because of structural reasons PARP9 and 13 do not belong
to this group functionally. They are explained below in more detail.
1.2.2.1 PARP10
PARP10 is the prototypical enzyme of the second subclass of the PARP family. This
150 kDa protein of 1025 aa was identified as an interaction partner of c-MYC in Jurkat
T-cells (Yu et al., 2005). MYC is a proto-oncoprotein functioning as a transcriptional
regulator, controlling different aspects of cell behavior including proliferation, differ-
entiation and apoptosis (Luscher, 2001). It is deregulated in the majority of human
cancers.
PARP10 is a ubiquitously expressed protein with some preference for cells of the
hematopoietic system. The highest expression levels can be found in spleen and thy-
mus.
The composition of domains in PARP10 is unique in the PARP family (Yu et al., 2005).
Between aa 13-80 an RNA recognition motifs (RRM) can be found. RRMs are known
to mediate binding to RNA and ssDNA (Crowder et al., 1999). A leucine-rich nuclear
export sequence (NES) (aa 598-607) mediates nuclear export of PARP10, a nuclear
localization sequence (NLS) could not be identified (Yu et al., 2005). Nevertheless,
PARP10 shuttles between nuclear and cytoplasmic compartments. A glycine-rich do-
main (aa 281-399) functions together with RRM in RNA binding (Ginisty et al., 2001).
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Figure 1.4 – Domain architecture of PARP10
Domains of PARP10 according to the CCDv2.06 Database. aa 13-80 RNA-binding mo-
tif; aa 598-607 Nuclear Export Signal; aa 650-667 and aa 673-690 two Ubiquitin Interac-
tion Motifs; aa 819-1025 PARP Domain; aa 884-931 homology region to PARP1. Figure
from (Schreiber et al., 2006).
A glutamte-rich region is present between aa 588-697. Furthermore PARP10 reveals
two ubiquitin interaction motifs (UIM) (aa 650-667 and aa 673-690). The poly(ADP-
ribose) polymerase region (aa 819-1013) reveals homology to the catalytic domain in
other PARP enzymes. The two conserved amino acids in the active center, H887 and
G888, are important for enzymatic function.
In humans the gene resides on the long arm of chromosome 8 (8q24.3). In mice the
Parp10 gene locus overlaps with the Plectin1 gene and they share common use of ex-
ons (Lesniewicz et al., 2005). Plectin1 is a protein that connects cytoskeletal filaments
and junctional complexes. Homozygous mutations are found in patients with Epi-
dermolysis bullosa simplex and muscular dystrophy. The head-to-tail organization of
the Parp10 and Plectin1 genes is a potential source of conflict for knockout strategies
in mice possibly causing interference with the expression of both genes (Lesniewicz
et al., 2005).
Recently the crystal structure of PARP10’s catalytical domain has been solved (SGC
Stockholm, in press http://www.rcsb.org/pdb/explore.do?structureId=
3HKV. The core structure elements of PARP10’s catalytical domain are histidine
(H887) involved in NAD+-binding and tyrosine (Y919). Both amino acids belong to
the highly conserved ”HYE” triad in the PARP superfamily but the glutamate found
in the first group of the PARP family is replaced by an isoleucine (I987 in PARP10).
The amino acid sequence connecting the β-4 and β-5 strand is only 6 residues long
in comparison to PARP1, where 37 amino acids separate these conserved strands.
The loop region differs throughout the family members and is postulated to mediate
substrate specificity. PARP enzymes with short loop regions are considered to be
more specific since the geometrical constraints required for modifications are greater
than those for the more conventional type of PARP enzymes (Kleine et al., 2008).
PARP10 preferentially modifies acidic residues of core histones and itself at E882,
which was shown to be the major acceptor site for PARP10-auto-ADP-ribosylation.
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ADP-ribose is ester-bonded to the substrate (Kleine et al., 2008). PARP10’s interaction
partner c-MYC is not ADP-ribosylated by PARP10 (Yu et al., 2005).
PARP10 function can be inhibited by some broadly acting PARP inhibitors like benza-
mide whereas more selective PARP1-inhibitors like PJ-34 are inefficient in inhibiting
PARP10. Neither intact nor broken DNA activates enzyme activity, which rather de-
creases upon incubation with DNA (Kleine et al., 2008).
The lack of the glutamate in the catalytic center suggested that PARP10 may use a
different enzymatic mechanism. Indeed, a new mechanism of action was postulated
recently for PARP10. An acidic target residue of the substrate functionally substi-
tutes for the catalytic glutamate, a mechanism referred to as substrate assisted catal-
ysis (Kleine et al., 2008). In PARP1 the catalytic glutamate functions to stabilize the
oxocarbenium ion transition state during the ADP-ribosylation reaction.
Because PARP10 lacks the glutamate, the site of modification also fulfills the function
of the catalytic glutamate and must therefore occupy a position close to where the
catalytic glutamate would normally reside. The PARP10 ADP-ribosylation reaction
proceeds through an oxocarbenium ion transition state which is described as a fully
dissociative SN1-type of mechanism. These findings were obtained by mutation of
single amino acids and structural models on the basis of PARP1, 3 and 12’s crystal
structures (Kleine et al., 2008).
PARP10 inhibits MYC and E1A-mediated cotransformation of rat embryo fibrob-
lasts by interference with entry into S-phase (Yu et al., 2005). Overexpression sup-
presses colony formation in HeLa cells (Kleine et al., 2008). Chou et al. report CDK2-
dependent phosphorylation at threonine 101 and concentration in the nucleolus dur-
ing late G1/S phase (Chou et al., 2006). Information on the physiological role of
PARP10 is rare but it might be involved in regulation of chromatin and gene tran-
scription as well as nuclear and cytoplasmic transport (Yu et al., 2005).
1.2.3 PARP Family Group III
The third group of the PARP family is reported to lack catalytic activity com-
pletely(PARPs 9 and 13). The catalytic glutamate in the active center which is im-
portant for the ADP-ribosylation reaction as well as the conserved histidine which is
required for NAD+-binding are absent in this group. Auto-ADP-ribosylation capac-
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ity is neither postulated nor described for these enzymes (Aguiar et al., 2005), (Kleine
et al., 2008).
The 96 kDa and 854 aa long PARP9 belongs to the macro PARPs and has been dis-
covered in patients with certain types of diffuse large B-cell lymphomas. This is an
aggressive lymphoma that makes up about 40% of lymphomas in young adults. It
promotes malignant B-cell migration, causing the high mortality in patients carrying
this mutation (Aguiar et al., 2000).
1.3 Bacterial toxins
Bacteria produce an array of cytotoxins which differ in structure, mode of action
and eukaryotic targets. Many toxins are enzymes that can modify their targets in
a catalytic manner. These sometimes irreversible modifications are responsible for
their high potency, presenting them as notorious killers responsible for thousands of
deaths annually including cholera, diarrhea of enterotoxic Escherischia coli, whooping
cough, diphtheria and many more (Aktories and Barbieri, 2005), (Holbourn et al.,
2006). Bacterial toxins were the first enzymes discovered employing mono(ADP-
ribosyl)ation as the mechanism of action, therefore they are described here (Ueda
and Hayaishi, 1985). ADP-ribosyltransferases are also described in mammals. Mam-
malian ARTs constitute a family of structurally related proteins expressed on the cell
surface or secreted into the extracellular compartment. The five paralogs (ART1-
5) are reported to play a role in myogenesis as well as innate and adaptive immu-
nity (Glowacki et al., 2002), but they are not part of this work.
At least five distinct groups of bacterial toxins modifying different targets can be dis-
tinguished (Holbourn et al., 2006).
Cholera, pertussis and E.coli enterotoxin are famous members of the AB5 family dis-
playing group 1, which targets small regulatory G-proteins. The enzymatically active
part of the toxin, the A-subunit, is situated on a scaffold consisting of a pentamer of
the B-subunit.
Cholera toxin (CT) causes massive diarrhea. After oral-fecal ingestion of Vibrio
cholera, usually by contaminated drinking water, the bacteria secrete their toxin into
the lumen of the gut. The B-pentamer recognizes the GM-1 ganglioside on the host
cell surface inducing endocytosis and translocation into the cytosole. After several
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Figure 1.5 – Structural alignment of PARP1, PARP2 and Corynebacterium diphteriae
toxin
Overlay of the conserved chain folds of the crystal structure of chicken poly(ADP-
ribose) polymerase 1 (PARP1, blue), mouse PARP2 (margenta) and Corynebacterium
diphteriaea toxin (yellow) catalytic fragments. The NAD+-binding site can be deduced
from the location of NAD+ (red), which is bound to the catalytic domain of the toxin.
The letters c, d, g and m indicate β-strands, and the letters J, K and L indicate α-
helices.The poly(ADP-ribose)-acceptor-binding site is marked by the ADP moiety of
bound carba-NAD+ (green). The conserved E988 is shown in orange. The striking
similarity between eukaryotic PARPs and prokaryotic toxins indicates that these en-
zymes are evolutionarily related. Figure from (Schreiber et al., 2006).
activating steps CT ADP-ribosylates G-proteins, which will then maintain their acti-
vated GTP bound state. This leads to an extensive upregulation of adenylate cyclase
and the subsequent increase in the amount of cyclic AMP. This can lead to a major loss
of ions and fluids from the intoxicated intestinal cells and gives rise to life-threatening
diarrhea and fluid loss (Holbourn et al., 2006). The pathogenic mechanism of entero-
toxic E. coli is comparable.
Group 2, which is represented by Diphteria and Pseudomonas exotoxin A, targets a
diphptamide residue, a modified histidine amino acid found in elongation factor 2
(EF2). These toxins are multidomain proteins with receptor binding, transmembrane
targeting and protease-resistant catalytic domains. The ADP-ribosylation of EF2 in-
terrupts its function in host cells disturbing protein synthesis, which results in funda-
mental physiological changes leading to cell death.
The third group are actin-targeting AB binary toxins which make up the biggest
group consisting of different Clostridiae-toxins including C. difficile, perfringens and
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botulinus. Binary toxins obviously contain two domains, a catalytic domain (A for ac-
tive) and a cell-binding domain (B for binding). ADP-ribosylation of their target actin
prevents actin polymerization by capping the exposed ends of the actin filaments,
which leads to cell rounding and eventually cell death due to break down of the actin
cytoskeleton (Holbourn et al., 2006).
The last two groups are the clostridial C2 and C3 exoenzymes, these are playing a so
far unknown role in bacterial pathogenesis (Holbourn et al., 2006).
Enzymes capable of transfering the ADP-ribose moiety are characterized by a con-
served NAD+ binding core with a central 6-stranded β-sheet (Glowacki et al., 2002),
(Otto et al., 2005), (Hottiger et al., 2010). A structural alignment of diphteria toxin
and PARP1 showing the striking homology is depicted in figure 1.5. All toxin groups
share the catalytic glutamate at the N-terminus of β5 responsible for the ADP-ribosyl
transferase activity, the same linear order of five conserved β-strands, a similar mode
of NAD-binding and a role for the loop between the beta4 und beta5 in substrate
binding (Holbourn et al., 2006), (Hottiger et al., 2010). These structural elements are
also found in PARP1.
Recently, Hottiger et al. have proposed a new nomenclature for all mammalian
ADP-ribose transfering enzymes including ARTs and PARPs (Hottiger et al., 2010).
Based on structural analysis including crystallography they proposed the groups
HYE, HYE variant and RSE, named by the conserved amino acids. Bacterial tox-
ins with mono(ADP-ribosyl)ation capacity can be integrated into these groups eas-
ily, underlining the necessity of understanding both mammalian and bacterial ADP-
ribosylating enzymes.
1.4 Methodology of substrate identification
1.4.1 Protein-protein-interaction
Studying protein-protein interactions is one of the most challenging fields in molecu-
lar biology. An important part of this work aims at finding new substrates of PARP10.
Proteins can form durable protein complexes, in which the chemical structure is nor-
mally not altered but effects on folding are possible, or the interaction can occur in
a very transient manner. Enzyme-substrate interactions are a special subgroup of
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protein-protein interactions, which are transient and include the covalent modifica-
tion of the substrate by the enzyme. The added group is normally provided by a
co-factor. This modification of proteins can itself change protein-protein interactions.
In the following section I want to present some of the commonly employed methods
and discuss their potential in terms of substrate finding. Some methods closely re-
semble each other; therefore it is necessary to have some general considerations in
mind.
In general, it is preferable to perform protein-protein interaction studies in vivo be-
cause post-translational modification (PTM) may have an impact on binding and in-
teraction capacity of the proteins. Furthermore, proteins, which interact in vitro, are
not necessarily coexpressed in the same cell or tissue type or are present in distinct
cellular compartments. In vivo studies avoid these biases.
Affinity approaches employing purification via different tags are widely favored
methods. Introducing a tag into a protein means to tolerate the consequences of a
possible interaction with the protein’s function. The tag could abolish protein func-
tion, influence affinity or affect subcellular localization of the protein. If possible, it is
therefore advisable to use both N- and C-terminally tagged proteins in each experi-
ment, to minimize these effects.
Another facet of affinity approaches is that they are highly biased towards proteins
of high abundance as well as high affinity (von Mering et al., 2002). Low expression
levels might result in an underrepresentation in the purified complex and subsequent
false negative non-detection of the interaction, while high affinity might lead to an
overrepresentation. During purifications, protein interactions with fast kinetics (high
Kon, high Koff) or low affinity might not be found. Hence, affinity-based methods
are biased towards proteins that interact with high affinity and with slow kinetics of
dissociation (Berggard et al., 2007).
During the washing steps in the purification process it is always a difficult balance
between the attempt to reduce unspecific binding and the effort to recover low affinity
targets from the protein complex. A setscrew are the washing buffers which could
range from mild to very stringent.
The above mentioned concerns are applicable to all of the methods described here-
after, which makes them unsuitable for substrate screening.
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1.4.2 Tandem Affinity Purification
Tandem Affinity Purification (TAP) is a method that allows to purify proteins ex-
pressed at physiological levels under native conditions. It was first described by
Rigaut et al. (Rigaut et al., 1999).
A TAP tag expression vector is fused onto a bait protein expression vector, the re-
sulting vector gets transfected into host cells and is expressed at nearly physiological
levels. The purification of the complex from the TAP tag containing the bait protein
including its interaction partners is performed in two steps via the TAP tag. This tag
consists of three parts, the calmodulin binding peptide (CBP), a Tobacco Etch Virus
(TEV) protease cleavage site and protein A, an IgG binding subunit of protein A of
Staphylococcus aureus. The first purification step occurs via protein A binding to IgG
beads.
This interaction can only be resolved under denaturing conditions, therefore the com-
plex is cleaved from the IgG beads by the TEV protease.
The TEV protease cleavage is highly specific because the TEV cleavage site motif is
rare in mammalian proteins (Berggard et al., 2007) and the protease works at fairly
low temperatures which reduces dissociation of the protein complex. The second
affinity purification occurs via CBP on calmodulin beads in the presence of calcium.
EGTA, which chelates Ca2+, resolves the binding under mild conditions and releases
the purified protein complex.
Members of the protein complex can be identified by mass spectrometry (MS) analy-
sis. These steps are summarized in figure 1.6. The above mentioned concerns espe-
cially towards kinetics are also relevant with respect to Tandem Affinity Purification.
1.4.3 Co-Immunoprecipitation
Co-Immunoprecipitation (CoIP) is another method widely applied to determine
protein-protein interaction and also functions as a pulldown approach.
With CoIP it is possible to search for two or more interacting proteins in a cell lysate.
The bait complexes are captured from the lysate by using a specific antibody to one
of the complex members.
Here two different approaches can be used. If a highly specific antibody against one
of the protein complex members exists, this can be used to pull down the complex
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Figure 1.6 – Tandem Affinity Purification
The purification occurs via two different tags provided by the TAP tag. Together they
grant a highly purified protein complex. Figure from (Puig et al., 2001).
from the native cell lysate. If such an antibody is not available, a tag can be intro-
duced to a bait protein. The resulting construct has to be transfected into the cells
and expressed at physiological or overexpressed levels.
After incubation of the lysate with the appropriate antibody the antibody-protein
complexes are pulled down by centrifugation with protein A or protein G beads.
These are sepharose beads coated with protein A or G, both are streptococcus mem-
brane proteins which bind specifically to the Fc part of most mammalian antibod-
ies. Washing removes unspecifically bound proteins. Finally the precipitated protein
complex is analyzed by SDS-PAGE.
Due to the relatively long purification, precipitation and washing steps, a stable in-
teraction between the proteins is required to detect new binding partners. Therefore
it is not suitable for enzyme-substrate interaction.
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Figure 1.7 – Phage Display
Phage Display cloning procedure for one round of affinity selection using an affinity
gradient column and a cDNA phage. At the end of the first round of selection, the
amplified phage can either be analyzed by DNA sequencing or directly subjected to
additional round(s) of selection. Figure from (Paul P Sche and Austin, 1999).
1.4.4 Phage Display
The Phage Display is also known as phage-based expression library screening, a tech-
nique to identify and clone genes which encode proteins that interact with a bait pro-
tein. This method was first described by Smith (Smith, 1985).
A bacteriophage library delivers cDNAs for proteins that are displayed as fusions to a
phage coat protein on the surface of the viral particle. The bait protein is immobilized
to a solid-phase support like a microtiter plate and incubated with the mixture of
phages expressing random proteins on their surface. After incubation and washing,
only the phages binding to the bait protein remain attached to the surface. After
elution, they can be used to produce more phages gaining a mixture that is enriched
for the relevant, well-binding phages. Repeating these steps several times selects for
the best binding phages.
Analizing their coding sequence reveals sequences coding for possible interacting
proteins or protein fragments. Still, the success of the method depends on the strength
of protein-protein interactions. Weak or transient interactions such as enzyme-
substrate interactions may not be detected.
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1.4.5 Yeast-two-Hybrid Systems
The Yeast two Hybrid (Y2H) System (Fields and Song, 1989) is another widely applied
method to study protein-protein interactions. A transcriptional activator includes the
promotor and the activator of transcription region upstream of the the gene to be
expressed. These DNA regions have to be connected by binding of several transcrip-
tion factors proteins to start transcription. The key to the two-hybrid screen is, that
in most eukaryotic transcription factors (TF) the activating and binding domains of
transcription are modular and do not necessarily interact directly. Therefor, any pro-
tein, that connects the TF containing the promotor binding domain (BD) and the TF
containing transcription activation domain (AD), can activate transcription.
The proteins supposed to interact are called bait and prey. Plasmids are constructed
coding for fusion proteins consisting of bait and AD as well as prey and BD. Ex-
pressed in yeast, these proteins can start transcription of a reporter gene if interact-
ing, e.g. β-galactosidase (See figure 1.8 for further information). It is possible to
use libraries fused to the prey construct facilitating screening for prey proteins inter-
acting with the bait. This relatively inexpensive method detects protein interactions
in vivo. Weak interactions are more likely to be detected because expression of the
reporter gene amplifies the signal (Estojak et al., 1995). If post-translational modifi-
cations (PTM) or correct folding are important, a proper expression system has to be
chosen. Originally described in yeast, Two Hybrid models also exist in mammals (Lee
and Lee, 2004). The investigation of multi protein complexes is not possible since only
binary complexes can be studied. Dual bait approaches slightly extend the field of ap-
plication. Unfortunately, Y2H systems reveal high rates of false positives. Up to 50%
of the identified proteins may be identified as false-positives (Deane et al., 2002).
1.4.6 Protein Arrays
The term protein array covers a wide area of applications and subsumes a diversity
of different methods (Templin et al., 2003). Protein arrays can be subdivided into
protein profiling arrays where multiple antibodies printed on glass slides are used
to measure protein abundance and/or alterations (Schweitzer and Kingsmore, 2002)
and functional protein arrays made up of every type of protein. Both types of arrays
are described schematically in figure 1.9. Functional protein arrays have a diverse set
of useful applications and will be described here.
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Figure 1.8 – Yeast two Hybrid System
Many eukaryotic transcriptional activators have two distinct functional domains, one
that binds to a promoter DNA sequence (BD) and one that activates transcription (AD).
For the Two Hybrid approach two plasmids are constructed. The first encodes the bait
protein and the BD. The second plasmid contains the target or bait protein and the
AD. If coexpressed in the same cell, bait and target protein can interact and restore the
transcriptional activation capacity from BD and AD which then induce transcription of
a downstream reporter gene. Figure from (Berggard et al., 2007).
A protein array can be a glass slide coated with a protein binding surface that hosts
a variety of purified proteins samples. The slide is then probed with a protein or
enzyme of interest. Interaction or modification is detected by one of the possibilities
explained later on.
The first whole-proteome microarray made and used in a functional assay consisted
of 5,800 proteins from yeast Saccharomyces cerevisiae spotted on nickel-coated glass
slides in order to identify calmodulin interacting proteins and a calmodulin binding
consensus sequence (Zhu et al., 2001). Manufacturing and developing such a protein
array involves solving many problems and requires consideration of different aspects.
First of all, it is necessary to convert genomic sequence information into thousands of
pure functioning proteins. Technology to solve this task already exist (cDNA cloning,
Polymerase Chain Reaction (PCR), recombinant protein expression, purification). To
express the proteins samples, the identification of the Open Reading Frames (ORF)
is fundamental. The ORFs differ with the organism to be studied. The first arrays
were designed for the lower eukaryote yeast, which lacks complex intron-exon struc-
tures. In higher organisms the identification of ORFs is not that simple, due to the
necessity of defining translational start sites and splicing signals. Furthermore, pro-
tein variations due to alternative splicing have to be taken into account defining the
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Figure 1.9 – Analytical versus functional protein microarray
A Analytical protein array. Different types of ligands, including antibodies, antigens,
DNA or RNA aptamers, carbohydrates of small molecules, with high affinity and speci-
ficity, are spotted onto a derivatized surface. These chips can be used for monitoring
protein expression level, protein profiling, and clinical diagnostics.
B Functional protein array. Native proteins or peptides are individually purified or
synthesized using high-throughput approaches and arrayed onto a suitable surface to
form protein arrays. These chips are used to analyze protein activities, binding proper-
ties, post-translational modifications and with an adequate detection method enzyme-
substrate interactions. Figure from (Phizicky et al., 2003).
ORFs.
After identification of the ORF a full length mRNA copy of all genes of interest must
be available. This implies a higher failure rate for very rare or very large mRNAs.
There are different attempts to create whole proteome cDNA libraries, e.g. the hu-
man Unigene collection of human fetal brain cDNA library (Bussow et al., 2000),
FLEX Full-Length expression gene repository (Brizuela et al., 2002), IMAGE Inte-
grated Molecular Analysis of Genomes and their Expression (Lennon et al., 1996)
or MCG Mammalian Gene Collection full length clone collection (Strausberg et al.,
2002).
The next step is to find an appropriate expression system. Escherichia coli and yeast
are easy to handle and low in cost, but as all prokaryotes, they lack PTM mechanisms.
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Braun et al. found, that only about 60% of likely soluble recombinant proteins are ac-
tually expressed in soluble form in E. coli, probably due to altered expression levels
and the lack of proper folding or modification, resulting in the generation of insol-
uble inclusion bodies (Braun et al., 2002). Insect cells, e.g. Sf9 cells may serve as an
alternative, because they provide PTM similar to modifications in mammalian cells
and, according to the Schweitzer group, generated 80% or higher rate of success in
producing soluble human proteins (Schweitzer et al., 2003).
The easiest way to extract the proteins from the cell lysates is by using a tag. These
are introduced as a fusion tag onto the ORF, a short peptide or protein that becomes
linked to each member of a set of proteins during expression vector construction.
Frequently used tags are Glutathione-S-transferase (GST), histidine (His)6, Protein A,
maltose binding peptide or FLAG peptide (Phizicky et al., 2003).
With high throughput methods thousands of protein samples can be generated. They
have to be printed onto coated glass slides in high spatial density and under care-
ful control of humidity, temperature and dust levels with stringently implemented
quality control processes.
Regarding the arrays surface it is possible to achieve random or oriented attach-
ment of the proteins. Polyvinylidene diflouride, agarose, polyacrylamide gel pads,
aldehyde or polylysine are materials allowing for random attachment, while nickel-
coated glass slides, together with N-terminal (His)6 fusion tags, obtain an oriented
fashion of attachment to the membrane (Zhu et al., 2001).
After probing and washing the array an appropriate detection method has to be cho-
sen which grants a high signal-to-noise ratio and should be moderate in instrumen-
tation costs (Schweitzer et al., 2003). Radioactive labelling may require long exposure
times for detection and implies adverse safety concerns. Chemiluminescence is also
a possible labelling method but exhibits signal bleeding and a limited dynamic signal
range. Fluorescence is the most favored labelling method as it stands for high sensi-
tivity and stability. Furthermore, fluorescent scanners tailored for microarray use are
available and microarrays can be archived for future imaging.
The application of protein arrays differs according to the set of proteins spotted on
the array. The ultimate form of a functional protein array would consist of all of the
proteins encoded by the genome of a special organism. A more appropriate term
for this type of array would then be proteome chip. Other sets of proteins could form
arrays containing families of proteins with similar biological activities, e.g. protein
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kinases, proteins expressed in the same tissue, proteins associated with a particular
state of disease or arrays of protein interaction domains (Espejo et al., 2002). Ques-
tions which could be answered employing protein arrays include protein-protein in-
teractions, antibody specificity profiling, immune response profiling, protein-small
molecule interactions in drug development or identification of enzyme-substrate in-
teractions.
Protein Arrays offer multiple advantages: low reagent consumption, rapid interpre-
tation of results and easy control of reaction conditions. This tool allows to rapidly
screen a high number of proteins for their biochemical behavior.
Obviously this method will not solve all molecular problems at once. For example
protein diversity resulting from RNA splicing is usually not well represented, mem-
brane proteins are always difficult to express and to purify. Furthermore there are still
proteins which cannot be expressed, solubilized or purified under the generic condi-
tions. Immanent with the system, proteins may be functionally inactive as fusion
proteins. Interference of the tag with the localization sequences during expression
in the cell cannot be excluded. Depending on the expression system certain post-
translational modifications may not be present in the recombinant system.
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2 Results
The presentation of the results is divided into two parts: The first part describes
the generation of siRNA-resistant vectors, the second part deals with different ap-
proaches to find new substrates of PARP10.
2.1 siRNA resistant vectors
Since its discovery in 2001 RNA interference (RNAi) is a widely used tool to knock-
down specifically single genes of interest (Elbashir et al., 2001). RNAi is the process of
sequence-specific, post-transcriptional gene silencing in animals and plants, initiated
by double-stranded RNA (dsRNA) that has a homologous sequence to the silenced
gene. The 21-nucleotide small interfering RNA (siRNA) duplexes specifically sup-
press expression of endogenous and heterologous genes in different mammalian cell
lines. Other dsRNA molecules in the cytoplasm of mammalian cells can trigger the in-
duction of interferon synthesis which leads to profound physiological changes (Stark
et al., 1998).
RNA interference induces degradation of the mRNA of the targeted gene. Comple-
mentary siRNA binds to a target mRNA which leads to an incorporation of the RNA
into a multiprotein complex known as the RNA-induced silencing complex (RISC).
Argonaute-2 protein (Ago-2) will then cleave the targeted mRNA at a defined po-
sition, followed by its degradation by cellular RNases. Gene transcription has then
come to a posttranscriptional halt (Rana, 2007).
RNAi disperse great enthusiasm on its therapeutical applicability. McCaffrey et al.
applied siRNA in adult mice to interfere with a sequence of the hepatitis C virus,
thereby demonstrating RNA interference in vivo (McCaffrey et al., 2002). A remain-
ing problem is how siRNA can be introduced into living tissues. Although medical
application seems possible it is far away from being used in patients. Nevertheless
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Characteristics Explanation
U or A at position 1 correlate with the rule of thermodynamic
asymmetry, the preferred nucleotides on
indicated positions may contribute to the bias
for selection of antisense strand
C or G (mostly C ) at Position 19
A and U richness
at position 1 and 7
A or U (mostly A) at position 10 the A or U at position 10 is at the cleavage site,
may promote catalytic RISC-mediated
passenger strand and substrate cleavage
U at position 17
Table 2.1 – Characteristics of effective siRNA
RNA interference arises as a powerful research tool to knockdown genes e.g. in cell
culture.
Henning Kleine developed effective siRNA to knockdown PARP10 expression in eu-
karyotic cells (PhD Thesis Dr. Henning Kleine). There are certain experimental sit-
uations in which it is useful to employ siRNA-resistant vectors. These are, for ex-
ample, complementation experiments like the knockdown of endogenous protein or
the overexpression of both siRNA-resistant wildtype and mutant proteins. Such an
experimental setting allows for the possibility to prove siRNA specificity as well as
analyzing the effects of mutants without the presence of endogenous proteins.
For this two vectors are cotransfected: One encoding the siRNA specific for the
mRNA of the protein of interest and the corresponding siRNA resistant vector, from
which the mutated protein to be examined is expressed. The siRNA represses the
mRNA of the endogenous protein while the expression of the mutated protein en-
coded by the resistant vector is maintained. Observed effects can be correlated to the
mutated protein more clearly.
There is considerable literature describing how to design effective siRNA (Pei and
Tuschl, 2006), (Kurreck, 2006), (Reynolds et al., 2004), and there is software available
which calculates the best siRNA sequences to a given base sequence (e.g. sidirect
(genomics.jp/sidirect)). Pei and Tuschl extracted five main characteristics of effective
siRNA from the broad literature (Table 2.1) (Pei and Tuschl, 2006). We took these char-
acteristics and designed a plasmid encoding PARP10, which should not be sensitive
to the siRNA. The positions are described using the guide strand as reference.
The resulting sequence should have the lowest affinity to the corresponding siRNA
without altering the amino acid sequence of the transcript. The comparison of the
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Figure 2.1 – siRNA-resistant vectors
The wildtype PARP10 vector (pEVRF0-HA-PARP10, referred to in domain structure
on top) was mutated by site-directed mutagenesis at the indicated sites (shown in red
letters in top, represents siRNA against PARP10) into the given bases (shown in bigger
letters in the middle, representing the siRNA resistant PARP10 vectors). Because of em-
ploying silent mutations, the amino acid structure (lane I) is not affected. The scheme
is not to scale and only refers to bp 945-963 (mutations G954C, T957A, A963T) and bp
1668-1686 (mutations A1677G, G1683C, C1686T) of the coding sequence of PARP10.
targeted region in the cDNA of PARP10 (HGNC database ID: 25895) with the rules
given by Pei and Tuschl resulted in the mutations G954C, T957A, A963T in pEVRF0-
HA-PARP10-sires_1 and A1677G, G1683C, C1686T in pEVRF0-HA-PARP10-sires_6.
To confirm the protein expression levels of the obtained vectors, they were cotrans-
fected in HEK 293 cells together with the corresponding siRNA. Protein levels were
analyzed by Western Blotting and immuno detection (Figure 2.2). Lanes 4 and 5 show
the sensitivity of the wildtypePARP10 RNA to the siRNAs against PARP10, there is
almost no protein detectable. Lanes 8 and 9 show pEVRF0-HA-PARP10-sires_1. The
RNA seems to be insensitive to siPARP10_1 but still suppressable by siPARP10_6.
Lanes 12 and 13 show this result vice versa for pEVRF0-HA-PARP10-sires_6. The
RNA of this construct seems resistant to the knockdown by siPARP10_6 but sensitive
to a knockdown by siPARP10_1. Green Fluorescent Protein (GFP) and tubulin were
also co-transfected in low amounts. GFP serves as transfection, tubulin as a loading
control.
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Figure 2.2 – Expression control of siRNA-resistant PARP10 vectors
HEK 293 cell were transiently co-transfected with constructs expressing HA-tagged
versions of PARP10 WT, PARP10res1 or PARP10res6 with the indicated siRNA con-
structs. pEQ176P2 was used as control. Protein expression was analyzed by Western
blotting. Co-expressed GFP served as transfection control, tubulin as loading control.
The experiment shown is representative of at least 3 independent experiments.
2.2 Tools to define new PARP10 substrates
2.2.1 Approaches employing peptide fragments
Kleine et al. identified the glutamate 882 (E882) as one of the major automodifica-
tion sites in PARP10 (Kleine et al., 2008). The glutamates, that are exposed on the
surface, have been determined with help of a structural model, which elucidates the
sterical proximity of the acceptor glutamate in the catalytic cleft of PARP10. This
proximity is necessary to get the substrate enzymatically modified according to the
proposed mechanism of substrate-assisted catalysis. The four surface exposed glu-
tamates E866, E870, E877, and E882 were chosen as candidates for automodification
and changed into alanines. The PARP10 mutant E882A was significantly less auto-
ADP-ribosylated. Thus, E882 seems to be one, but not the only, important acceptor
site for PARP10 auto-ADP-ribosylation (Kleine et al., 2008).
Having an antibody recognizing the ADP-ribose-modification specifically would fa-
cilitate gaining insight into PARP10’s physiological function enormously but unfor-
tunately such an antibody does not exist yet. One approach to generate such an anti-
body would involve the generation and subsequent ADP-ribosylation of a substitute
peptide which can afterwards serve as an antigen for the immunization of e.g. rabbits.
With this background a PARP10 peptide was designed which carries the automodifi-
cation site E882 and some surrounding amino acids.
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Figure 2.3 – E882 PARP10 peptide modeled into PARP10’s catalytic cleft
Detail from the residues surrounding the E882 site of modification modeled into the
catalytic cleft of PARP10. Residues from the substrate are illustrated with the carbon
atoms colored in cyan. The E882 occupies a position where it probably stabilizes the
oxocarbenium ion transition state which is necessary to catalyze the transfer of ADP-
ribose. NAD+ is depicted in yellow. Figure from (Kleine et al., 2008).
The 1.7 kDa peptide’s amino acid sequence is CRRPVE882QVLYHG . The cystein at the
N-terminus does not belong to the original PARP10 sequence but serves for coupling
to other chemical groups. The first step of this project was to adress whether the
PARP10 peptide can be enzymatically modified.
The ADP-ribose modification is realized enzymatically in a PARP assay. For further
analysis the modified peptide has to be separated from the PARP assay reaction mix-
ture. The low M.W. excluded separation by SDS-PAGE, hence other methods were
necessary. We decided to introduce a biotin tag into the the peptide coupled to the
Figure 2.4 – Biotinylation through thioether bond formation using Iodoactyl-PEO2-
Biotin
Figure from Pierce, Product Information 0254.3.
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N-terminal cystein. The biotin tag allows different experimental approaches due to
its strong binding to Avidin and Streptavidin, which can only be resolved under de-
naturing conditions. We used Iodoacetyl-PEO2-Biotin (Pierce) that reacts specifically
with cysteines adding a biotin group with a linker of 0.6 kDa to the peptide. The
iodoacetyl group reacts with the sulfhydryl (-SH) group and forms a stable thioether
bond. The PARP10 peptide was incubated with a fourfold excess of the biotinyla-
tion reagent in the dark at ambient temperature. After 90 minutes of incubation the
biotinylated protein (ca. 2.4 kDA) was separated from the reaction mixture via a
desalting column. Concentration of the elution fraction containing the biotinylated
PARP10-peptide was determined with a microBCA test.
2.2.1.1 Pulldown of the PARP10 peptide
We subjected the non-tagged and the biotinylated peptide (bio-peptide) to a PARP
assay and offered β-NAD+ as cofactor together with radioactively labelled 32P-NAD.
The incubation of the reaction mixture with Streptavidin sepharose beads pulled
down the modified peptide fraction that was subsequently analyzed by Cerenkov
counting.
As a first approach, we compared the pulldown of the bio-peptide to non-tagged
peptide and to a reaction mixture without any peptide. Relative counts bound to
Streptavidin-coated beads are 5-fold increased compared to the control samples (Fig-
ure 2.6A).
These findings suggest that the bio-peptide can be separated specifically from the
reaction mixture. The incorporation of label strongly suggests modification of the
peptide by the PARP10 enzyme.
As a second approach we designed a competition experiment by offering both tagged
and non-tagged PARP10 peptide. Unrelated peptides were used as a control. Myb-
peptide (ARR PRH SIY SSD DDE EDV EMY DHD YDG LLP K) contains three gluta-
mates and other acidic amino acids; Myc peptide (KFE LLP TPP LSP SRR SG) contains
one glutamate. The substrate glutamates are required as a reacting agent to stabilize
the oxocarbenium ion transition state which occurs during the transfer of the ADP-
ribose moiety, according to the proposed mechanism of substrate assisted catalysis.
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Figure 2.5 – ADP-ribosylation of a peptide containing a PARP10 automodification site
The pulldown experiments were carried out as a direct and a competition approach. In
the direct approach biotinylated PARP10 peptide was subjected to a PARP assay. Sub-
sequently, the peptide was separated from the reaction mixture by a pulldown with
Streptavidin sepharose beads. Incorporated label was measured by Cerenkov count-
ing. In the competition approach both biotinylated and non-tagged peptide were en-
zymatically modified. This should lead to a reduction of radioactivity bound to the
Streptavidin beads.
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Figure 2.6 – Pulldown of the PARP10 E882 peptide
A The reaction mixture contained the indicated amounts of peptides. Relative counts
bound to the Streptavidin sepharose beads were measured by Cerenkov counting and
normalized to background (reaction mixture without any peptide).
B Competitive PARP assay with subsequent pulldown. The incorporation of label was
analyzed by Cerenkov counting. Depicted are the relative counts bound to the Strep-
tavidin sepharose beads normalized to counts in a pulldown of biotinylated peptide
alone. The indicated amounts of peptide are given in micrograms. Both experiments
were performed at least twice with similiar findings. Vertical black bars indicate stan-
dard deviation.
A 2.5-fold excess of non-tagged peptide resulted in a 2-fold decrease in pulled down
radioacitivity. Competition with the control peptides also led to a slight decrease
(Figure 2.6B).
2.2.1.2 Separation of the PARP assay using Tricine SDS-PAGE
Despite the promising outcome of the pulldown experiments we searched for a more
direct method to analyze the peptide’s modification. Therefore we chose Tricine SDS-
PAGE established by Schagger (Schagger and von Jagow, 1987). Instead of glycine
used as the trailing ion in the Laemmli-SDS PAGE, tricine is used here. The different
pKS of tricine enables these gels to separate proteins in a M.W. range between 1 and
100 kDa. This tool enabled us to analyze the peptide directly.
By carrying out the enzymatic modification in a PARP assay and separating the pep-
tide from the reaction mixture by Tricine SDS-PAGE, we were able to analyze the
incorporation of label in the peptide band of the dried gel by autoradiography. The
Coomassie Blue dyed tricine gel (Figure 2.7) reveals the separation of the reaction
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Figure 2.7 – Separation of the PARP assay using Tricine SDS-PAGE
A PARP assay was performed and the reaction mixture was electrophoretically sepa-
rated on a tricine gel. Shown is a coomassie blue (CB) stained tricin gel (top panel)
and an autoradiograph (32P, bottom panel, peptide bands marked with asterisks). The
amount of incorporated label was determined by autoradiography.
mixture into two fractions, representing the peptide and the PARP10 enzyme. The
autoradiography shows incorporated radioactivity in lanes 9 and 10 in the PARP10
band and in the peptide band. These findings support our hypothesis that the E882
peptide is modified by PARP10.
2.2.2 Substrate pulldown in cell lysate
In an attempt to find new PARP10 subtrates we tried to pulldown ADP-ribosylated
proteins from a cell lysate. Therefore we prepared a cell lysate of HEK 293 cells in TAP
lysis buffer. In order to clear the lysate from NAD, the lysate was purified on a NAP-5
column, which separates proteins from low-molecular components. The cleared pro-
tein solution was subjected to a PARP assay using biotinylated NAD (bioNAD) as
co-factor with full-length C-TAP-PARP10 or with the catalytically inactive mutant C-
TAP-PARP10-G888W. Biotinylated proteins were then pulled down with Streptavidin
beads. The pulldown fractions were divided into two parts and each part was sep-
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Figure 2.8 – Substrate searching in a cell lysate
The lysed and cleared cell lysates where subjected to a PARP assay. The subsequent
pulldown fraction was separated by SDS-PAGE and analyzed by Western Blotting and
silver staining. In the upper panel without PARP inhibitor GST-PARP10 fragment 5
detected with α-GST was used, in the lower lane with PARP inhibitor PJ34 full length
C-TAP-PARP10 was used as enzyme, detected by an PARP10 antibody.
arated by SDS-PAGE. One part was then analyzed by immunodetection via Western
Blotting to detect automodification of the catalytically active enzyme. The other part
was silver stained on order to detect possible bands representing ADP-ribosylated
proteins.
We expected to see differences in the band patterns of the catalytically active and the
inactive enzyme sample, e.g. no pulldown of enzyme in the sample with PARP10-
GW in the Western blot or additional bands in the silver staining of the WT sample.
Unfortunately we did not.
It might be that this lack of difference was caused by the predominant activity of other
PARPs, e.g. PARP1. We repeated the experiment and inhibited PARP1 by the PARP
inhibitor PJ-34. Still, no difference was detectable (Figure 2.8).
In all samples we could detect the PARP10 enzyme, respectively PARP10#5 or
PARP10-GW, in the Western blot.
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2.2.3 Protein Screen
As an alternative approach we wanted to perform a high-density substrate screen.
We wanted to use the comercially available KSI ProtoArray (Invitrogen). This array
allows for substrate screening in a total of more than 8,000 proteins. These proteins
are spotted onto a glass slide coated with a thin layer of nitrocellulose. It is available
in a human and, with other specifications, in a yeast version.
High density protein arrays are most often used to search for kinase substrates. They
have not been used to study ADP-ribosylation reactions yet.
The array is organized into 4 columns with 12 rows resulting in 48 subarrays. Each
subarray is arranged into a square of 4400x4400 µm with 20 rows and 20 columns of
spots. The median spot diameter is 150 µm with a spot center to center spacing of 220
µm and a distance between subarrays of 100µm. Each sample is printed twice on the
screen. To offer different detection options several control samples are spotted, e.g.
α-GST, Streptavidin-HRP, AlexaFluor antibodies and several buffer controls.
Proteins spotted on the array correspond to the human Ultimate™ ORF (open read-
ing frame) Clone Collection, a proprietary Invitrogen collection which corresponds
to the GenBank® amino acid sequences. Each ORF is expressed as an N-terminal
GST-fusion protein in insect cells using a baculovirus expression system. Proteins
expressed in insect cells are similar to those expressed in mammalian cells with re-
spect to protein folding and post-translational modifications such as phosphorylation
and glycosylation (Bouvier et al., 1998), (Hollister et al., 2002), (Predki, 2004). These
proteins are more likely to be functional than proteins expressed in E. coli. The pu-
rification process is optimized to gain a maximum of soluble recombinant proteins
by a generic GST purification process under native conditions in a high-throughput
format (Schweitzer et al., 2003).
We used the ProtoArray Human Protein Microarray mg v4.0 for our experiments,
containing over 8,000 human proteins
2.2.3.1 Preliminary Experiments
We used PATH™ Protein Microarray Slides (GenTel) for our preliminary experi-
ments. They provide exactly the same surface as the KSI ProtoArrays (Invitrogen).
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Figure 2.9 – Binding to the nitrocellulose surface and solid phase assay with bio-NAD
A The indicated amount of GST-PARP10#5-GW, GST-PARP10#5-WT and GST were
spotted onto a GenTel nitrocellulose glass slide and then blocked in 5% BSA. Detec-
tion was performed with an rat α-GST antibody and α-rat-HRP.
B Solid phase PARP assay with biotinylated NAD. Enzyme reactions where carried
out with 3 µg C-TAP-PARP10 and 25 mM bio-NAD. The transfer of bio-ADP-ribose
was detected by chemiluminescence via Streptavidin-HRP.
For pilot studies we prepared small scale arrays with a few samples on our own. This
included sample preparation, spotting, drying and blocking in 5% BSA.
First, we confirmed that our samples bind to the glass slide. Therefore samples were
spotted on the slide and were detected by an α-GST antibody after blocking and
washing (Figure 2.9A).
The next question was if PARP10 still modifies its substrates in solid phase assays.
Therefore we incubated the prepared slides with a PARP assay reaction mixture con-
taining biotinylated NAD (Trevigen). We detected the incorporation of biotin via
chemiluminescence with streptavidin-HRP (Figure 2.9B). After washing in 1% PBS-T
imaging was proceeded on a Typhoon imager.
The result of this experiment showed that the known substrates of PARP10 are
still modified in solid phase assays. The dark spots predominantly in the PARP10-
wildtype (WT) sample suggest incorporation of biotin, indicating the usage of spot-
ted proteins as exogenous substrates.
The two main detection methods of ADP-ribosylation modifications are labelling
with radioactive NAD (32P-NAD or 33P-NAD) visualized by autoradiography or la-
belling with biotinylated NAD which allows for chemiluminescent as well as fluores-
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A
B
H2
Figure 2.10 – Molecular structure of biotin-NAD
A Molecular structure of NAD.
B Molecular structure of biotin-NAD. The tag is of a reasonable size compared to the
original molecule. The dotted lines indicate where the nicotinamide group leaves the
molecule when it is coupled onto a protein as ADP-ribose .
cent visualization via different Streptavidin-tagged reagents. The use of radioactive
NAD has the advantage that no steric modification of the cofactor is introduced by
the radioactive phosphor isotope. In our preliminary experiments we also used 32P-
NAD as a modification marker, but the obtained signal did not fit the needs for the
ProtoArray (data not shown). In contrast, labelling with a biotin group could hin-
der the enzymatic reaction because of its size in proximity to the catalytic cleft. The
structural differences of NAD and bio-NAD are depicted in figure 2.10. However, bi-
otinylated NAD has been successfully used to study ADP-ribosylation reactions and
is easier to handle than radioactively labelled NAD (Brown and Marala, 2002), (Jør-
gensen et al., 2008). Finally, we employed Streptavidin AlexaFluor647 (Invitrogen) to
detect incorporated biotinylated ADP-ribose because it offers high sensitivity as well
as high resolution. Again, BSA and GST serve as a negative control; Alexa 647 was
used as a positive control.
Known PARP10 substrates are PARP10 itself as well as the catalytically inactive mu-
tant PARP10-GW and the four core histones. The PARP10 proteins were expressed as
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Figure 2.11 – PARP10 solid phase assay with biotin-NAD
Four PARP assays with three different concentrations of enzyme were performed on
Nitrocellulose covered glass slides (Gentel). Reaction for 30’ at 30◦ C. 125 ng of the in-
dicated proteins were spotted in duplicates on the slides. Biotinylated NAD in the indi-
cated amounts was used as cofactor. Modified Proteins were detected by Streptavidin-
coupled AlexaFluor647. Slides were read out on a Typhoon imager (Amersham).
GST fusion proteins. We used the PARP10 fragment 5 that contains the catalytical do-
main from aa 818 to 1025. Thus GST is an important negative control to prove that the
protein and not the GST tag gets modified during the enzymatic reaction. BSA was
also used as a negative control. The reaction took place at 30◦ C and was incubated
for 30 minutes. The overal liquid volume on the slide was 120 µl.
In the control slide without C-TAP-PARP10 enzyme in the reaction mixture PARP10-
WT incorporates label, which indicates automodification. In the three slides with
PARP enzyme in the reaction mixture, all known substrates incorporate label.
PARP10-GW, PARP10-WT, a mixture of all four core histones and pure H2B exhibit
signal. The mixture of core histones seems to be the best, PARP10-GW a less marked
PARP10 substrate. Higher amounts of bio-NAD as well as free PARP10 enzyme result
in more intense signals (Figure 2.11).
These encouraging results show that the known substrates still react in solid-phase
assay designs. It is reasonable to assume that our experimental conditions will func-
tion with the original KSI ProtoArray.
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+ C-TAP PARP10
- C-TAP-PARP10
AlexaFluor Ab
buffer
biotin Ab
GST gradient
potential subtrates
* * * * * * * *
*
* *
Figure 2.12 – PARP10 ProtoArray
Shown is a ProtoArray probed with C-TAP-PARP10 enzyme and bioNAD and the con-
trol array probed without enzyme. Biotinylation was detected by Streptavidin Alex-
aFluor 647, visualized by the microarray scanner Axon 4100. The bottom panel shows
the enlarged view on one subarray. AlexaFluor is depicted in Ab blue, Biotin Ab in
pink, buffer in green, GST gradient in yellow and potential substrates in orange boxes.
In the white areas, marked with asterisks, air bubbles prevented modification of the
spots. The scans are inverted and converted to gray scale.
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2.2.3.2 ProtoArray
We used reaction conditions as determined in our test experiments (PARP10 enzyme
0.7 µg, 25 µM bio-NAD, 30◦ C, 30’) in an overall volume of 120 µl to probe ProtoAr-
rays. The procedure to probe the protein arrays hardly differed from those represent-
ing the solid phase assays. We washed the arrays in RIPA buffer, a rather stringent
buffer to reduce nonspecific binding of components and labeling to a minimum. The
developed arrays were then scanned the array on an AXON 4100 microarray scanner
suitable for the analysis of high-density microarrays.
After scanning the pixel intensity values were calculated by a microarray data acqui-
sition software. We used GenePix® Pro (Molecular Devices Corporation), which is
able to divide the protein array into multiple independent scans and analysis areas.
It finds and analyzes features of any shape. Thus, the data acquisition also includes
spots of bad spot morphology and adjusts different background intensities, which
can also be seen on our array slide (Figure 2.12, compare background of left to right
side).
Intensities of negative controls were used to calculate background intensity. GenePix
Pro then generates a file containing the results of the screen which consists of the
location of the spot, the corresponding protein ID and the z-score.
z =
x− µ
σ
x: raw value; µ: population mean; σ: standard deviation of the population
The z-score is an important statistical parameter and behaves reciprocally to the p-
value which describes the statistical relevance. A z-score of e.g. z=3 corresponds to a
p-value of p=0.001349. We analyzed our results with a z-score of z=2.5, corresponding
to a p-value of p=0.00621, resulting in about 40 hits listed according to their z-score
(Table Hits of the ProtoArray). Once significant signals were identified, we confirmed
these signals using visual identification as recommended by the manufacturer.
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Protein Full protein name Database ID z-Score
PDGFB Platelet-derived growth factor beta polypeptide PHG0046 10.6
Histone Histone (unfractionated whole histone) Sigma
H9250
10.2
Histone_F2a2 Histones H2a and H4 Immuno-
Vision
HIS-1002
9.8
CCL19 Chemokine (C-C motif) ligand 19 PHC1244 9.7
IL-21 Interleukin 21 PHC0215 9.4
FGF12 Fibroblast growth factor 12 NM_004113.3 6.0
PRKG2 cGMP-dependent protein kinase type II PV3973 4.8
CCDC55 Coiled-coil domain-containing protein 55 NM_032141.1 4.8
PLK1 Polo-like kinase 1 PV3501 4.7
SLAIN2 SLAIN motif-containing protein 2 BC031691.2 4.5
IL-4 Interleukin 4 PHC0045 4.4
CAR-LBD Constitutive Androstane receptor, ligand
binding domain
PV4838 4.2
La La protein AAA51885.1 4.1
ZNF706 Zinc finger protein 706 NM_016096.1 4.0
CXCL1 Chemokine (C-X-C motif) ligand 1 PHC1066 3.5
PCCA Propionyl Coenzyme A carboxylase, alpha
polypeptide
NM_000282.1 3.5
SYT1 Synaptotagmin I NM_005639.1 3.5
GSK3A Glycogen synthase kinase 3 alpha PV3270 3.4
ACVR1 Activin A receptor, type I PV4877 3.3
ROBO3 Roundabout, axon guidance receptor, homolog
3
BC008623.1 3.2
KCNAB1 Potassium voltage-gated channel,
shaker-related subfamily, beta member 1
NM_172160.1 3.1
BMPR1A Bone morphogenetic protein receptor, type IA NM_004329.1 3.1
TRIM52 Tripartite motif-containing 52 NM_032765.1 3.1
C1ORF131 chromosome 1 open reading frame 131, protein
of 292 aa
CAI21985.1 3.1
MARK4 MAP/microtubule affinity-regulating kinase 4 PV3851 3.0
C16ORF78 postulated 265 aa protein of chromosome 16
open reading frame 78
Q8WTQ4.1 3.0
WDR5 WD repeat domain 5 NM_017588.1 3.0
FKBP3 FK506 binding protein 3 NM_002013.2 2.9
GSK3B Glycogen synthase kinase 3 beta PV3365 2.8
AURKA Aurora kinase A PV3612 2.8
YY1 YY1 transcription factor NM_003403.3 2.8
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CDK5 Cyclin-dependent kinase 5 PV3000 2.8
CEACAM6 Carcinoembryonic antigen-related cell adhesion
molecule 6
BC005008.1 2.7
C6ORF201 postulated 196 aa protein of chromosome 6
open reading frame 201
Q7Z4U5.2 2.7
ATP5C1 ATP synthase, H+ transporting, mitochondrial
F1 complex, gamma polypeptide 1
BC000931.2 2.7
PIK3CA Phosphoinositide-3-kinase, catalytic, alpha
polypeptide
PV4788 2.6
GPRC5C G protein-coupled receptor, family C, group 5,
member C
BC004925.1 2.6
IKBKE* Inhibitor of kappa light polypeptide gene
enhancer in B-cells, kinase epsilon
PV4875 2.6
PRKCB1 Protein kinase C, beta 1 P2291 2.6
PRUNE2 Prune homolog 2 NM_138818.1 2.5
Table 2.2 – Hits of the Protoarray
46
3 Discussion
3.1 siRNA resistant vectors
With the help of siRNA-resistant vectors a tool to analyze the effect of exogenous
PARP10 in the absence of endogenous protein has been developed. As explained be-
fore, they are used to specifically knockdown the endogenous protein while expres-
sion of the transfected construct is mantained. By this means effects of e.g. protein
mutants with altered or missing function can be assessed directly, their effects are
not masked by endogenous proteins. As this tool is especially intended to analyze
additional mutant constructs, the mutations, which are going to be introduced into
the vector expressing a siRNA-resistant wild type PARP10 protein, are not allowed
to overlap with the fragment complementary to the siRNA to avoid abolishing the
resistance.
PARP10-expressing vectors which are resistant to pSuper si PARP10#1 and #6
have been created. The resistance of pEVRF0-HA-PARP10-sires_1 and pEVRF0-HA-
PARP10-sires_6 to the siRNAs siPARP10_1 and siPARP10_6, respectively, has been
shown on protein level (Figure 2.2). Since the effects of the siPARP10#1 and #6 have
been shown to be reversible, this is another hint for the specificity of the siRNA con-
structs against PARP10.
In further experiments it would be important to verify, respectively, some of the basic
functions of the protein encoded by pEVRF0-HA-PARP10-sires vectors. Although
no major functional differences are expected since the amino acid structure has not
been changed, the enzyme activity, effects on cell proliferation and the subcellular
localization of the protein should be determined.
It could be shown that the siRNA against PARP10 is specific and, most importantly,
it will now be possible to test the functionality of the different domains of PARP10 in
a setting with minimal endogenous protein expression. This may reveal new aspects
of PARP10 biology.
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3.2 Tools to define new PARP10 substrates
3.2.1 Approaches employing a peptide fragment
With the help of the PARP10 peptide CRRPVE882QVLYHG containing the automod-
ification site, an antibody recognizing the ADP-ribose modification shall be created.
First, it had to be demonstrated that the peptide is indeed modified by PARP10 and
second, that the enzymatic reaction occurs with sufficient efficiency to obtain high
labeling stoichiometry. For immunization purposes a sufficient amount of modified
peptide has to be purified.
There were two different experimental setups to measure the modification of the pep-
tide. The first was a pulldown assay of the biotinylated peptide with Streptavidin
beads, the second was the direct examination of the peptide after separation on tricine
gels.
In the pulldown experiments the direct approach led to a fivefold increase in incor-
porated radioactivity. This shows that the biotinylated peptide was radioactively la-
belled indicating modification by PARP10. ADP-ribosylation of the peptide using this
approach was highly reproducible. A 2.5-fold excess of non-tagged peptide reduced
the incorporated radioactivity to the half (Figure 2.6).
An important question that remain open is why this peptide is a rather poor substrate
of PARP10. A probable posibility is that the peptide does not display the same three-
dimensional structure around E882 as in the complete PARP10 enzyme. The lack
of the appropriate structure may considerably reduce binding of the peptide to the
catalytic site. The biotin peptide might be influenced positively by the tag, allowing
for a more native folding perhaps leading to a better enzyme-peptide affinity.
The unspecific peptides of which Myb had 3 glutamates and Myc one glutamate led
to a slight decrease of incorporated radioactivity on the beads. This may be due to
unspecific modification of the many glutamates present in these peptides by PARP10.
But if the presence of just one glutamate is able to reduce incorporated radioactivity,
this questions our hypothesis of a specific modification.
In addition to structural determinants in the vicinity of E882, other regions of sub-
strate PARP10 might be relevant for an efficient interaction with enzyme PARP10.
The lack of these additional regions in the peptide might also contribute to the find-
ing that the peptide is a poor substrate.
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We performed an experiment with which we tried to evaluate the interaction be-
tween peptide and PARP10 fragment 5. In a pulldown experiment we tested whether
the catalytic domain of PARP10 interacts with Streptavidin beads coated with bio-
peptide. There was no specific binding detectable (data not shown).
This finding is consistent with the rather weak modification of the peptide. Together
these studies suggest that E882 indeed is substrate of PARP10 but that in the con-
text of a peptide, the affinity to the enzyme is only weak, indicating that additional
determinants are required for efficient enzyme substrate interaction.
We wanted to further evaluate the hypothesis that the peptide is a substrate of
PARP10 using a more direct approach. Tricine gels are able to separate proteins in
a range between 1 and 30 kDa. Thus, the 2.4 kDa substrate peptide should be sepa-
rated on such a gel from other components present in a PARP assay. It should even
be possible to discriminate between biotinylated and non-tagged PARP10 peptide as
peptide and bio-peptide migrated with a difference of about 0.5 kDa .
The substrate peptides (bio-peptide 2.4 kDa; non-tagged peptide 1.7 kDa) migrated
higher than expected (at approx. 5 kDa) (Figure 2.7). It is unlikely that the biotin tag
influenced the electromobility of the peptide, because the untagged peptide was also
running too slow regarding its M.W. Furthermore, we were not able to obtain sharp,
focused bands.
The different incorporation of radioactive label in the tagged and non-tagged peptide
band (more in the tagged band) may be due to different peptide concentration levels.
There is no explanation for the unspecific signal visible around 26.6 kDa in the au-
toradiography which is also visible in 32P-NAD only sample (Figure 2.7, lane 2). The
clearest labelling was visible for the bio-peptide band, while both peptide bands in-
corporated radioactive label . This supports our hypothesis that the PARP10 peptide
is substrate of PARP10.
To further optimize the experiment it is advisable to use peptides with other tags
that are larger in molecular weight and improve resolution on different gels, e.g. his-
tagged peptides, which would also allow for different pulldown experiments. It may
also be worth optimizing buffers and running conditions to get more reliable results
with the tricine gels and also to try other gels.
The tricine gels are an interesting alternative to SDS-PAGE if low M.W. proteins have
to be separated. With some adjustments of the procedure they might be included in
the methods employed in our lab.
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As a completely different approach High Pressure Liquid Chromatography (HPLC)
can be employed to separate the PARP10 peptide from the other compontents of a
PARP assay. HPLC separation of ADP-ribosylated proteins or peptides has been used
successfully to analyze ADP-ribosylation of substrates at arginine residues (Tsuchiya
et al., 1986). It should be possible to detect the modified peptide in comparison to the
untagged peptide without modification because of altered behavior on appropriate
columns. As a next step the modified peptide fraction could be purified in a quanti-
tative manner.
3.2.2 Substrate Pulldown in Cell Lysate
In an attempt to find new PARP10 subtrates we tried to pulldown ADP-ribosylated
proteins from a cell lysate (Figure 2.2.2). By desalting the cell lysate we made sure that
endogenous NAD was removed. Normally NAD is present in excessive amounts
in cell lysates and would interfere with sufficient labelling with bioNAD. The cell
lysate was subjected to a PARP assay with the catalytically active PARP10-5 fragment,
followed by a pulldown of the biotinylated proteins from the lysate, which were then
separated by SDS-PAGE. The first experiment showed bands in the Western Blot in
the PARP10-5-WT as well as in the PARP10-5-GW sample. No signals were expected
in the sample with the catalytically inactive PARP10-5-GW mutant.
As no differences in the band patterns were detectable, a possible explanation might
be the presence of other active PARPs, especially PARP1, in the cell lysate. PARP1
is known to ADP-ribosylate many different proteins in vitro, perhaps masking ADP-
ribosylation of substrates by PARP10. Therefore, in the next experiment we inhibited
PARP1 activity with the PARP inhibitor PJ-34, a potent and highly specific PARP1
inhibitor (Abdelkarim et al., 2001).
Nevertheless, no difference was detected upon silver staining of proteins between
WT- and GW- sample, suggesting that at this level of resolution no specific substrates
could be detected. As the pulldown was carried out in TAP-lysis buffer, which is
very mild, it would by worth trying more stringent conditions to minimize unspecific
binding to the Streptavidin beads. Obviously, endogenously biotinylated proteins are
also captured by the Streptavidin beads.
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3.2.3 Protein Screen
For our preliminary experiments we used PATH™ Protein Microarray Slides and
spotted the samples ourselves. Because the slides are very sensitive to dust particles,
which increase background signals, best results in spot morphology were obtained
with sterile filtration of every solution that got into contact with the screen. To fur-
ther improve the spot morphology we tried to spot different amounts of protein. We
tested between 5 to 250 ng of protein in volumes between 0.125 and 0.5 µl. Best results
were received with 125 ng protein in a volume of 0.5 µl (data not shown). The prepa-
ration of the slides was carried out at 4◦C to avoid improper folding of the proteins
due to ambient temperature. We did not concentrate on optimizing the spot morphol-
ogy because the procedure performing the final protein screen on the protein arrays
from Invitrogen did not include spotting.
Labelling via bio-NAD and detection with Streptavidin-AlexaFluor 647 resulted in
cleaner screens than the radioactive method, which we also tried. There was a good
signal-to-noise ratio due to low background. Differences in the amount of enzyme or
co-factor clearly led to an alteration in the incorporation of label (figure 2.11, compare
lanes 3 and 4).
Independent from the detection method, automodification of PARP10 was detectable
on the control slides (figure 2.11, - C-TAP-PARP10). This indicates that enzyme activ-
ity is not affected by the solid phase assay design and suggests proper protein folding.
GST was not modified according to figure 2.11. GST was an important negative con-
trol, because both the samples in our preliminary experiments as well as the proteins
on the ProtoArray are GST-tagged.
The single shot experiment with the ProtoArray was successful. Due to high back-
ground levels some adjustements to the procedure will be necessary for future ex-
periments. Reducing background will be one important aspect, possibly by using a
blocking agent on polymere basis (e.g. Roti-Block, Carl Roth), which offers advan-
tages in specificity and signal strength. Due to accidental trapping of air bubbles be-
low the cover slip a special cover slip should be used that avoid air bubble trapping,
e.g. LifterSlips (Nunc). Additionally, washing which was carried out in 1% BSA in
PBS-T could be changed to more stringent conditions (e.g. RIPA) to further decrease
background signals.
All together, the array experiments should be repeated.
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With a z-score of 2.5 40 proteins have been identified as hits. A higher z-score of z=
3.0 would result in 27 hits (Table Hits of the Protein Array). 40 hits correspond to
0.5% of proteins on the array. This seems to be a reasonable number of identified
hits. Verification in an in-solution PARP assay will be necessary before further anal-
ysis on the functional relationship between PARP10 and the new substrate is worth
pursuing. Since histones, which were identified previously as in vitro substrates of
PARP10, could also be identified as targets on the array, a first impression of validity
is given. ADP-ribosylation of histones has been described previously and is well doc-
umented (Smith and Stocken, 1975), (Okayama et al., 1977), (Riquelme et al., 1979).
Figure 3.1 summarizes the different sites of ADP-ribosylation in histones that have
been identified yet. Most of the modification sites have been mapped in the late 1970s
and early 1980s.
Linker as well as core histones are known to be mono-ADP-ribosylated (Hassa et al.,
2006). It should be noted that the functional consequences of these modifications are
poorly understood. In our screen we identified core histones exclusively and did not
identify linker histones which are also represented on the ProtoArray.
Histone modifications are likely to control the local surface structure and function of
chromatin (Fischle et al., 2003), (Strahl and Allis, 2000). Distinct histone modifica-
tions on one or more histone tails are supposed to act sequentially or in combination
to form a histone code, which can be interpreted by other proteins to bring about
distinct downstream events. Given the many different modifications that can occur
on the histones it is unlikely to expect a clear on-off phenomenon studying one sin-
gle modification, nevertheless this is observed for some modifications. At present it
is unclear whether mono- or poly-ADP-ribosylation plays a role in controlling chro-
matin function. Poly-ADP-ribosylation of histones is thought to be linked to DNA
repair processes and cell proliferation (Kreimeyer et al., 1984), (Kleine and Lüscher,
2009).
To underline the utility of the protein array for studying ADP-ribosylation it would be
worth to determine the true positive rate of the hits after confirming them in further
experiments. Invitrogen observes a true positive rate of approximately 80% for serin-
threonine protein kinases while using the human ProtoArray.
Once verified, the substrates have to be evaluated regarding different aspects. First,
PARP10 and its possible substrate have to appear in the same subcellular compart-
ment. Second, to be physiologically relevant, they have to be coexpressed in the same
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Figure 3.1 – Summary of known histone modifications in the human linker and core
histones
Shown are the indicated modification and their mapped site.
R: mono(ADP-ribosyl)ation mark; Ac: Acetylation mark; P: Phosphorylation mark;
Me: Methylation Mark; Ub: Ubiquitinylation mark; B: Biotinylation mark Adapted
from (Hassa et al., 2006).
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tissue types and in the same cell cycle phases. Especially the physiological relevance
of the secreted factors identified in the screen is doubtful since up to now no connec-
tion of PARP10 to the secretory compartment has been found. A classical secretion
signal has not been found in PARP10 during computarized analysis. It would be
possible to test whether PARP10 is secreted by analyzing serum or the supernatant
medium of a cell culture expressing PARP10.
After confirming the ProtoArray hits via in-solution PARP assays they have to be ana-
lyzed bioinformatically to answer burning questions, e.g. for the existence of consen-
sus sequences for substrate recognition. If consensus sequences could be identified, it
would be possible to do Genome Mining for proteins that contain these consensus se-
quences in order to predict additional substrates analogous to kinases and their sub-
strate consensus sequences. In the field of kinase research many consensus sequences
are known, which are useful to predict whether a substrate is phosphorylated by a
kinase of interest. Also in the field of poly-ADP-ribosylation metabolism there were
attempts to define poly-ADP-ribose binding concensus sequences for non-covalent
interactions (Pleschke et al., 2000), (Gagné et al., 2008). With these pieces of informa-
tion it might be possible to gain insight into the mechanism of PARP10’s substrate
specificity. If it depends on the primary amino acid sequence, this could result in
defining consensus sequences. If secondary and tertiary structure are important, the
substrates defined here could be analyzed by aligning their crystal structures to iden-
tify strucutural motifs that might be critical for being a PARP10 substrate. Substrate
specificity and recognition is not restricted to alterations at the catalytic cleft: distal
docking sites, scaffolds or subcellular localization might also have an impact on the
enzymatic activity of PARP10.
As the ProtoArray was successful for PARP10, it could be applied to other PARPs in
order to obtain information about an ADP-Ribosylome. Therefore, appropriate bioin-
formatic algorithms are required to analyze the results and to put them into a greater
context. It would be worth knowing how many sites exist in the proteome which are
able to be ADP-ribosylated analogous to estimation of the number of phosphoryla-
tion sites in order to underline the importance of phosphorylation as a posttransla-
tional modification (Ubersax and Ferrell, 2007).
The Girolamo Lab established another screening method to detect mono-ADP-
ribosylated proteins (Dani et al., 2009). They used the macro domain, a protein
module that interacts specifically with ADP-ribose, as selective baits for high-affinity
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purification of mono-ADP-ribosylated proteins, which were then identified by mass
spectrometry. They concentrated on the identification of cellular targets of ADP-
ribosylation reactions catalyzed by cellular ADP-ribosyltransferases and toxins.
The macro domain affinity purification approach could also be done with cell lysates
subjected to a PARP10 Assay or with cell lysates of cells with overexpressed PARP10
protein. These would be an approach more similar to in vivo experiments, that
avoided bias by differential expression patterns of PARP10 and its substrates.
Finally, using protein arrays to study ADP-ribosylation reactions is a new method
which provided promising results. It will be worth using it in future experiments.
There are various questions that might be answered employing protein screens. They
might reveal consensual substrate recognition sequences, and applied for the entire
PARP-family, the generation of a ADP-ribosylome seems reasonable.
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4 Experimental Procedures
4.1 Consumables and Reagents
Consumables
Consumables were purchased from: Amersham Biosciences, Ansell, Becton Dickin-
son, Beranek, Biometra, Bio-Rad, Brand, Braun, Corning, Costar, Eppendorf, Falcon,
Fisher Scientific, Fuji, Gentel, Greiner, Hartenstein, Integra Biosciences, Kimberley-
Clark, Merck, Millipore, Nalgene, Nerbe Plus, Nunc, Roth, Sarstedt, Sartorius, Schle-
icher& Schuell, Stratagene, Terumo, TPP, VWR, WillCo Wells
Reagents
Reagents met at least the criteria for the purity standard p.a. and were purchased
from: Amersham Biosciences, AppliChem, Baker, Bayer, BD Biosciences, Biozym,
Calbiochem, Clontech, Delta, Difco, Fluka, GE Healthcare, Gibco, Invitrogen, Jack-
son Immuno Research, KMF, Fermentas, Merck, MP Biomedicals, New England Bi-
olabs, Perkin Elmer, Qiagen Riedel-de-Haën, Roche, Rockland, Roth, Sigma, Strata-
gene, Trevigen, USB, Zymo Research
4.2 Oligonucleotides
forSIresPARP10_6 ggacacaggccttgaggaggtcgatcctaccgaggcc
revSIresPARP10_6 ggcctcggtaggatcgacctcctcaaggcctgtgtcc
P10-E306A ggggtctctggaacatgcggggctggtaag
P10-E398A gctggggcaggcgggcctggtgg
P10-E409A catggactcaccagcgcaagaggggctgg
P10-E441A ggcagggcaggcgggcctggtgg
P10-E409A_rev ccagcccctcttgcgctggtgagtccatg
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4.3 Plasmids
Plasmid Description
pEVRF0-HA This vector encodes the expression of
N-terminally HA tagged proteins in eukaryotic
cells under control of a strong CMV promoter. The
vector contains pSP65 plasmid sequences, a
human CMV promoter/enhancer, the translation
initiation region from the HSV thymidine kinase,
the splicing and polyadenylation signals from the
rabbit β-globin gene and the SV40 origin of
replication.
pEVRF0-HAPARP10 The full-length cDNA encoding the 1025 aa
PARP10 protein was ligated into pEVRF0-HA
from pSport-p150 T+B using the KpnI and XbaI
restriction sites (S. Schreek).
pEVRF0-HAPARP10-
G888W
This vector was obtained from
pEVRF0-HA-PARP10 by site-directed mutagenesis
using the oligos PARP10G888Wfor and
PARP10G888Wrev (E. Poreba).
pSupersiPARP10#1
and 6
These vectors were derived from pSuper by
insertion of the hybridized oligos siPARP10#1 an 6
between the BglII and HindIII sites. They drive the
expression of shRNAs designed for targeting the
PARP10 mRNA (C. Cornelissen, H. Schuchlautz).
pEVRF0-HA-PARP10-
sires_1
This vector was obtained from
pEVRF0-HA-PARP10 by site directed mutagenesis
using the oligos forSIresPARP10_1 and
revSIresPARP10_1 (A. Braczynski.)
pEVRF0-HA-PARP10-
sires_6
This vector was obtained from
pEVRF0-HA-PARP10 by site directed mutagenesis
using the oligos forSIresPARP10_6 and
revSIresPARP10_6 (A. Braczynski).
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pRetroSuper-siRes_1 and
6
This vector was obtained from ligating the insert
pSupersiPARP10_1 into the 6110 bp backbone
from pRetroSuper_luc 3 after digestion with XhoI
and EcoRI (A. Braczynski).
pRetroSuper-siRes_6 This vector was obtained from ligating the insert
pSupersiPARP10_6 into the 6110 bp backbone
from pRetroSuper_luc 3 after digestion with XhoI
and EcoRI (A. Braczynski).
pSuper-siLuc#2 This vector drives the expression of a functional
shRNA targeted against the luciferase mRNA
from the histone H1 PolIII promoter (C.
Cornelissen).
pEGFP-F This vector encodes farnesylated enhanced green
fluorescent protein. Because it remains attached to
the plasmamembrane, it can be detected by
fluorescence microscopy in fixed cells. EGFP-F is
designed for use as a cotransfection marker
(Clontech).
pEQ176P2 This vector was routinely used for control
transfections for CMV-containing vectors
whenever the respective backbone vector for the
transfected plasmid was not available. It is
derived from pEQ176 which drives expression of
β-galactosidase under control of a CMV promoter.
Most of the cDNA encoding β-galactosidase was
cut out by a PvuII restriction digest (J.
Lüscher-Firzlaff).
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4.4 Antibodies
Antibody Description
α-GFP (FL) Polyclonal rabbit antibody that recognizes full
length GFP from Aequorea Victoria as well as EGFP
and ECYFP (Santa Cruz Biotechnology).
α-HA (3F10) Monoclonal rat IgG1 antibody that recognizes the
HA peptide sequence (YPYDVPDYA) derived
from the influenza hemagglutinin protein, even if
the HA peptide is introduced into unrelated
recombinant proteins by ”epitope tagging”
(Roche).
α-Tubulin-a (DM1A) Monoclonal mouse antibody that recognizes the
peptide sequence of tubuline
(alekdyeevgvdsvegegeeegee)(E. Kremmer).
α-GST Rabbit anti GST (glutathion-s-transferase)
antibody (E. Kremmer).
Alexa 647 Streptavidin
conjugate
This conjugate is a bright, far-red fluorescent
probe with excitation and emission characteristics
identical to Cy5 dye (650/668 nm). Streptavidin is
a nonglycosylated biotin-binding protein which is
isolated from bacteria (Invitrogen).
α-rabbit IgG + IgM
(H+L) HRP- conjugated
(111-035-144)
Horseradish Peroxidase (HRP)- conjugated
secondary antibody from goat which recognizes
the heavy and light chains of rabbit IgG and IgM
antibodies (Jackson Immuno Research).
α-rat IgG + IgM (H+L)
HRP- conjugated
(112-035-068)
HRP-conjugated secondary antibody from goat
which recognizes the heavy and light chains of rat
IgG and IgM antibodies (Jackson Immuno
Research).
α-mouse IgG + IgM
(H+L) HRP- conjugated
(115-036-068)
HRP-conjugated secondary antibody from goat
which recognizes the heavy and light chains of
murine IgG and IgM antibodies (Jackson Immuno
Research).
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4.5 Work with nucleic acids
4.5.1 DNA preparation
DNA was extracted from transformed bacteria according to the manufacturer’s in-
structions. For small-scale preparations the Zyppy Plasmid Miniprep Kit (Zymo Re-
search) and for preparative purpose the Qiagen Plasmid Maxi Kit (Qiagen) were used.
4.5.2 Quantification of Nucleic Acid
Nucleic acid content was quantified at 260 nm by UV-Spectrometry (NanoDrop, Ther-
moScientific). The optical density = 1 corresponds to a concentration of approxi-
mately 50 µg/ml double-stranded DNA. The ratio of a measurement at 260/280 nm
allows determination of DNA purity.
4.5.3 Enzymatic Manipulation of Plasmid DNA
10x Magic Buffer
• 200 mM Tris pH 7.5
• 700 mM NaCl
• 200 mM KCl
• 100 mM MgCl2
• 0.5 mM spermine
• 0.125 mM spermidine
T4 DNA Ligase (Fermentas)
Plasmid DNA was digested in 20 µl reaction volume using restriction enzymes (Fer-
mentas) with magic buffer for 1h to o/n at 37◦ C. After electrophoretical separation
of the fragments of interest and subsequent recovery from the gel with the Zyppy
Gel DNA Recovery Kit (Zymo Research) following the manufacturer’s instructions,
T4 DNA ligase (Fermentas) was used to ligate sticky-ends o/n at ambient tempera-
ture. (Rouleau et al., 2004)
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4.5.4 Agarose Gel Electrophoresis
TBE
• 89 mM Tris-Base
• 89 mM boric acid
• 2 mM EDTA
10x DNA Loading Buffer
• 50 mM Tris pH 8.0
• 50 mM EDTA
• 50% (v/v) glycerol
• 0.25% (w/v) bromophenol blue
• 0.25% (w/v) xylene cyanol
O‘GeneRulerTM 1 kb DNA Ladder Plus (Fermentas)
Agarose Low EEO (Sigma)
Gel electrophoresis of DNA was performed as described (Sambrook et al., 1989). Di-
gested or plasmid DNA was mixed with 10x DNA Loading Buffer and then separated
electrophoretically in 1% agarose gels (Sigma). The running conditions were 84V for
45’ for gels of the size 12x8 cm in TBE-Buffer. For visualization the gels contained
0,1 µg/ml ethidiumbromide which intercalates into the DNA and makes the DNA
fragments visible at 340 nm light wave length.
4.5.5 Site-directed Mutagenesis
Primers for site-directed mutagenesis were designed using the online available
QuikChange Primer Design Program (Stratagene). The mutagenesis of single or
flanking base pairs was performed using the QuikChange Site-directed Mutagene-
sis Kit (Stratagene) according to the manufacturer’s instructions. The PCR reaction
was performed under the following conditions:
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Cycle Repetition Temperature (◦C) Time
First Denaturation 1 95 30”
Denaturation 95 30”
Anealing 2 55 30”
Elongation 68 4’
Denaturation 95 30”
Anealing 18 60 30”
Elongation 68 4’
Dpn I digest for 1h at 37◦ C destroyed the parental vector. 8 µl of the reaction mixture
was used to transform XL10 competent bacteria. Transformed bacteria were plated
on ampicillin LB agar plates and incubated over night. DNA of single colonies was
extracted in preparative scale and analyzed by sequencing.
4.6 Work with procaryotic cells
4.6.1 Bacteria Strains
Bacteria strain Description
E.coli XL10-Gold
(Stratagene)
Tetr D(mcrA)183 D(mcrCB-hsdSMR-mrr)173
endA1 supE44 thi1 recA1 gyrA96 relA1 lac Hte [F’
proAB lacIqZDM15 Tn10 (Tetr) Amy Camr],
E.coli BL21(DE3) pLysS
(Stratagene)
B F− dcm ompT hsdS(r−B m
−
B) gal λ(DE3) [pLysS
Camr]
4.6.2 Materials for Work with Prokaryotic Cells
LB Medium
• 1% (w/v) tryptone
• 0.5% (w/v) yeast extract
• 1% (w/v) NaCl
• pH 7.0
Low Salt LB Medium
• 1% (w/v) tryptone
• 0.5% (w/v) yeast extract
63
4. Experimental Procedures
• 0.5% (w/v) NaCl
• pH 7.5
TB Medium
• 1.2% (w/v) Tryptone
• 2.4% (w/v) yeast extract
• 4% (v/v) glycerol
• 17 mM KH2PO4
• 74 mM K2HPO4
Agar plates (Amp/Kan)
• LB Medium
• 1.5% (w/v) Bacto Agar (Difco)
• 100 µg/ml ampicillin or
• 30 µg/ml kanamycin
Agar Plates (Zeo)
• Low Salt LB Medium
• 1.5% (w/v) Bacto Agar (Difco)
• 50 µg/ml zeocin (Invitrogen)
4.6.3 Protocols for Work with Prokaryotic Cells
4.6.3.1 Bacterial Transformation
After thawing on ice 100 µl chemically competent bacteria were pipetted into a 14 ml
round bottom tube (Falcon) onto 100-1000 ng plasmid DNA without further mixing.
They were incubated on ice for 30 minutes, heat-shocked for 45 seconds at 42◦ C
and then replaced on ice for another minute. Next bacteria were allowed to grow
in 1 ml LB medium for 1h at 37◦ C with gentle agitation. Subsequently, cells were
pelleted by centrifugation, re-suspended in 100 µl LB medium and plated on LB agar
plates containing the appropriate antibiotic. Plates were incubated o/n at 37◦ C until
colonies were visible.
4.6.3.2 Purification of GST fusion proteins
TNE Buffer
• 20 mM Tris pH 8.0
• 150 mM NaCl
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• 1 mM EDTA
• 5 mM DTT
• 1 mM Pefabloc SC (Roche)
• 14 µg /ml aprotinin
GST Wash Buffer
• 100 mM Tris pH 8.0
• 120 mM NaCl
GST Elution Buffer
• 100 mM Tris pH 8.0
• 120 mM NaCl
• 20 mM glutathione
A couple of colonies of transformed bacteria were inoculated into a starter culture
of 50 ml LB medium including 0.4% (w/v) glucose and 1.0‰(v/v) Ampicillin. The
starter culture grew o/n at 37◦ C. 10 ml of the starter culture were diluted in 500
ml LB medium. The culture was grown several hours at 37◦ C until reaching an
OD600 ≈ 0.5-0.7. Addition of 1.0 mM IPTG induced the expression of the GST fusion
protein which took place o/n at ambient temperature. Subsequently, bacteria were
harvested by centrifugation at 5000xg. The pellet was resuspended in ice-cold TNE
buffer and lysed for 30 min on ice by 100 µg/ml lysozyme. Cells were further solu-
bilized by sonication (5x25 pulses at 70% power) and lysates were cleared from cell
debris by centrifugation at 10,000xg for 30 min. The supernatant was subjected to a
pulldown with 500 µl equilibrated Glutathione Sepharose 4B beads (SIGMA) per 30
ml of lysate for 1h at 4◦ C on a tube rotator. After three times washing with PBS beads
were transferred to a 0.8x4 cm chromatography column (Bio-Rad). On the column
the beads were washed once with 1 ml of GST wash buffer. The bound proteins were
eluted in three fractions with 300 µl of GST elution buffer each. In order to estimate
concentration and purity of the yielded protein in comparison to a BSA standard se-
ries, aliquots of the eluted proteins were subjected to SDS-PAGE and quantified by
Coomassie staining.
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4.7 Work with eukaryotic Cells (Cell Culture)
4.7.1 Eukaryotic cell lines
Cell line Description
HEK 293
(ATCC CRL-1573)
This is an adherent epithelial cell line derived from human
embryonic kidney (HEK) cells transformed with
Adenovirus 5 DNA. The Ad5 insert is integrated into
chromosome 19q13.2. It is a hypotriploid cell line with a
modal chromosome number of 64, occurring in 30% of
cells.
HeLa
(ATCC CCL-2)
This is an adherent epithelial cell line derived from a
cervical adenocarcinoma of a 31 year old black female.
100% aneuploidy is observed with a modal chromosome
number of 82. HeLa cells have been reported to contain
HPV-18 sequences. P53 expression was reported to be low,
and normal levels of pRB were found.
Flp-In™- T-REx
™–293-
pcDNA5/FRT/TO/
C-TAP-PARP10
This stably transfected cell line was generated by
transfection of Flp-In ™- T-REx™-293 cells with pOG44
and pcDNA5/FRT/TO/ C-TAP-PARP10. Stable cell lines
were obtained by selection with hygromycin B and
Blasticidin S.
4.7.2 Materials for Cell Culture Work
DMEM (Gibco) with 4.5 g/l glucose
PBS
• 140 mM NaCl
• 2.6 mM KCl
• 2 mM Na2HPO4
• 1.45 mM KH2PO4
Blasticidin S (Invitrogen) 10 mg/ml
Doxycyclin (Sigma) 1 mg/ml
Hygromycin B (Roche) 50 mg/ml
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Penicillin / Streptomycin (Seromed) 10.000 Units/ml / 10.000 µg/ml
Trypsin / EDTA (Seromed) 0.5 / 0.02% (w/v) in PBS
FCS (Gibco)
Tissue culture dishes (Sarstedt) ï¿½ 6 cm, ï¿½ 10 cm
4.7.3 Culture Conditions
All cell lines were cultured under humidified atmosphere of 5% CO2 at 37◦ C.
HEK 293 cells were cultured in DMEM supplemented with 10% (v/v) FCS and 1%
(v/v) Penicillin/Streptomycin. Stably transfected Flp-In™T-REx™-293 cell lines were
maintained in regular DMEM supplemented with 15 µg/ml Blasticidin S and 50
µg/ml hygromycin B.
4.7.4 Transient Transfection
CaCl2 250 mM
2x HeBS
• 274 mM NaCl
• 42 mM HEPES
• 9.6 mM KCl
• 1.5 mM Na2HPO4
• pH 7.1
HEPES buffer
• 142 mM NaCl
• 10 mM HEPES
• 6.7 mM KCl
• pH 7.3
The transient transfection of adherent cells e.g. HEK293 cells was performed ac-
cording to the calciumphosphate method (Bousset et al., 1994); (Chen and Okayama,
1988). Calcium ions form complexes with the double-stranded DNA which are then
precipitated by the addition of phosphate. The cells take up the DNA-calcium-
phosphate by endocytosis. About 4x105 cells were seeded on ï¿½ 6cm tissue culture
dishes and were allowed to grow for 24h. For transfection 6 µg of total DNA was
diluted in 200 µl 250 mM CaCl2 in a round bottom tube (Falcon) and incubated for
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up to 20 min at ambient temperature. Subsequently 200 µl 2x HeBS buffer was added
slowly, the solution mixed carefully and afterwards pipetted onto the cell monolayer.
The dishes were swayed and put back into the incubator for 6 hours, then remain-
ing precipitate was thoroughly washed away with 4 ml HEPES buffer. Cells were
cultivated 72 hours in fresh medium until harvested.
4.8 Work with Proteins
4.8.1 Peptides
Peptide Sequence
PARP10 peptide CRR PVE QVL YH
Myb CKII peptide ARR PRH SIY SSD DDE EDV EMY DHD YDG LLP
K
cMyc peptide KFE LLP TPP LSP SRR SG
4.8.2 Preparation of Whole Cell Lysates
RIPA Buffer
• 10 mM TrisCl pH 7.4
• 0.15 M NaCl
• 1% NP-40
• 1% Deoxycholate (DOC)
• 0.1% SDS
• 0.5% (v/v) Trasylol (Aprotinin)
• 2,5 U/ml Pepstatin
• 2.5 U/ml Leupeptin
• 0.15 mM Benzamidin
• 0.5 mM Pefabloc
All work was carried out at 4◦ C. After transfection with siRNA constructs cells were
allowed to grow for 72 hours before being harvested. Co-transfection with siRNA
constructs was routinely performed in a 3:1 ratio of siRNA to the corresponding gene
coding plasmid, e.g. 1.5 µg of vector and 4.5 µg of siRNA. Per ï¿½ 6cm tissue culture
dish 150 µl RIPA buffer with freshly added protease inhibitors was applied. After 5
minutes incubation on ice cells were harvested. Cell lysates were incubated on ice
another 10’ prior to sonication in a water bath sonicator (Bioruptor, Diagenode) for
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10’ at high intensity with pulse 0.5. Lysates were cleared from cell debris by centrifu-
gation (25’, 13,200 rpm, 4◦ C). The supernatant was transferred to a 1,5 ml reaction
tube and stored at -20◦ C. If the lysates were used for SDS-PAGE analysis solely, they
were mixed immediately with 4x sample buffer to allow longer storage periods.
4.8.3 Biotinylation of N-terminal Cysteins
Biotinylation Reaction Buffer
• 50 mM Tris HCl
• 5 mM EDTA
• pH 8,3
4 mM Iodoacetyl-PEO2-Biotin (Pierce) in Biotinylation Reaction Buffer
D-Salt™Polyacrylamide Desalting Column 1,800 MW
Micro BCA Kit (Pierce)
Iodoacetyl-PEO2-Biotin reacts specifically with Cysteins. The reaction of the
iodoacetyl group with a sulfhydryl (-SH) group is rapid and specific, especially if only
a slight reagent-to-sulfhydryl molar excess is used and the reaction is performed at
pH 8.3 (Product information, Pierce). The protein to be biotinylated was mixed in 4x
molar excess with freshly prepared Iodoacetyl-PEO2-Biotin. The reaction took place
at ambient temperature in the dark for 90’. Subsequently, modified and unmodified
peptide or protein were separated on a D-Salt™Polyacrylamide Desalting Column
1,800 MW with an exclusion range from 100-1,800 Daltons. It separates Iodoacetyl-
PEO2-Biotin, 542 M.W. from the biotinylated PARP10-peptide, ca 2,4 kDa. The Bi-
otinylation Reaction Buffer also served as Elution Buffer. Protein content of each 300
µl fraction was determined with a Micro BCA Kit (Pierce) according to the manu-
facturer’s instructions. By this method the peptide backbone and the three amino
acid residues Cysteine/Cystine, Tyrosine and Tryptophan lead to a reduction of the
cupric ion (Cu2+) to the cuprus ion (Cu1+) which is chelated by bichinonic acid (BCA)
forming an intense, purple colored complex linear to the amount of protein.
4.8.4 Pulldown with Streptavidin-Sepharose Beads
Streptavidin Sepharose™High Performance (GE Healthcare)
RIPA Buffer without Protease Inhibitors
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Pulldowns were performed in a 30 µl PARP Assay (see PARP Assay) which contained
biotinylated PARP10-Peptide. To stop the ADP-ribosylation reaction 1 ml RIPA Buffer
was added to the reaction mixture and incubated with 15 µl Streptavidin Sepharose
beads for 90’ at 4◦ C with permanent agitation on a tube rotator. After three times
washing in 1 ml RIPA Buffer the beads associated radioactivity was measured in 1 ml
RIPA buffer by Cerenkov counting (Liquid Scintillation Counter, PerkinElmer).
4.8.5 Denaturing Discontinuous Polyacrylamide Gel
Electrophoresis (SDS-PAGE)
2x/4x Sample Buffer
• 160 mM / 320 mM Tris pH 6.8
• 20% / 40% (v/v) glycerol
• 10% / 8% (w/v) SDS
• 0.25% / 0.5% (w/v) bromphenole blue
• 100 mM / 200 mM β-mercaptoethanol
5% Stacking Gel
• 0.13 M Tris pH 6.8
• 13.3% (v/v) acrylamid/ bisacrylamid (30%/0.8%)
• 0.12% (v/v) SDS
• 0.11% (v/v) APS
• 0.068% (v/v) TEMED
10% Resolving Gel
• 5% (v/v) acrylamid
• 0.057% (v/v) bisacrylamid
• 0.4 M Tris pH 8,7
• 0.035% (v/v) TEMED
• 0.1% (v/v) SDS
• 0.66% (v/v) APS
Running Buffer
• 25 mM Tris base
• 250 mM glycine
• 0.1% (w/v) SDS
PageRuler Prestained Protein Ladder, 11-170 kDa (Fermentas)
The discontinuous SDS-PAGE was essentially performed as described by Laemmli
(Laemmli, 1970), with a 5% stacking gel and a 10% separating gel. Negatively charged
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SDS binds to protein which is denatured due to cooking with β-mercaptoethanol.
The amount of SDS binding to the protein reflects the protein’s size. Because of this
linearity a mixture of different proteins can be separated according to their molecular
weight while moving through an electric field in a polyacrylamide gel matrix. The
stacking gel focuses the protein stack which gets subsequently separated by weight
in the running gel. Dependent on the sample’s volume they were mixed with 2x/4x
Sample Buffer and then incubated 3’ at 95◦ C. The probes were applied to the gel with
a Hamilton syringe. The running conditions were 200V for 45’ for MiniGels and 30
mA per gel for 180’ for regular gels.
4.8.6 Tricine-SDS-PAGE
Cathode buffer
• 0,1 M Tris base
• 0,1 M tricine
• 0,1% (w/v) SDS
• No adjustment of the pH!
Anode buffer
• 0,02 M Tris base
• pH 8,9
Tris- Tricine Sample Buffer
• 2ml 4x Tris-Cl/SDS, pH 6,8
• 24% (v/v) glycerol
• 8% (w/v) SDS
• 0,2 M DTT
• 0,02% Coomassieblue G-250
4x Tris-Cl/SDS
• 6,05%(w/v) TrisCl
• 0,4% SDS
• pH 6,8
Precast Gel System Ready Gel Tris Tricine Gel 16,5% Resolving Gel (Bio-Rad)
Polypeptide SDS-PAGE Standard Size Range 1.4-26.6kDa (Bio-Rad)
Tris-Tricine gels have another separation capability due to their different trailing ion.
Tricine Gels are able to separate proteins and peptides in a range of 1-100 kDa with
best results between 5 and 30 kDa.
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Tricine (pK 8.15) differs with its trailing properties from glycine (pK 9.6). At the usual
pH values between 6.8 and 8.8 tricine migrates much faster than glycine in the stack-
ing gel despite its higher molecular mass, because much more tricine is in the migrat-
ing anionic form. As a consequence, the stacking limit is shifted to the low-molecular-
mass range. Therefore the stacking and destacking of the proteins can be achieved at
lower acrylamide concentrations than those in the glycine system.
In combination with Coomassie Blue which is used as the tracking dye, this method
is capable to separate peptides. Comassie Blue runs a little faster than the smallest
proteins in the gels, in contrast to the commonly used bromphenol blue which runs
behind the smallest proteins. Although Comassie Blue migrates as a broad band
it allows to monitor the separation progress in the gel without losing the smallest
peptides by too long electrophoresis times. The method was performed according to
Schagger (Schagger and von Jagow, 1987).
Samples were diluted 1:2 in Sample Buffer, then heated for 5’ at 95◦ C, 40 µl of each
probe were applied to the Ready Gel Tris-Tricine Gel. The Protein Standard (Bio-Rad)
was diluted 1:20 in Tris-Tricine Sample Buffer and also heated for 5’ at 95◦C. 5 µl per
well were used for the Mini gels. 200 ml Cathode Buffer and 1000 ml Anode Buffer
were filled into the appropriate chambers of the electrophoresis apparatus (Bio-Rad).
The outer anode chamber was completely filled with buffer for better control of heat
development. Electrophoresis ran at 150V for about 150’.
4.8.7 Rapid-Coomassie-Staining
Fixing Solution
• 40% (v/v) methanol
• 10% (v/v) acetic acid
Staining Solution
• 10% (v/v) acetic acid
• 0.006% (w/v) Coomassie Brilliant Blue G-250 (Bio-Rad)
Destaining Solution
• 10% acetic acid
Coomassie Blue stains proteins unspecifically through interaction with cationic and
hydrophobic amino acid residues. After SDS-PAGE, the glycine-gels were stained for
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1 hour under slight agitation. In order to reduce background staining, the gel got
destained o/n in dH2O. For Tricine Gels a modified procedure was followed due to
the high mobility of the separated fragments which makes elution during the stain-
ing process highly probable. After running gels were fixed in Fixing Solution, then
stained in Staining Solution and afterwards destained 4 times in Destaining Solution.
Each step lasted 30’. Short staining and destaining periods are necessary in order to
minimize elution of the peptides.
4.8.8 Silver Staining
Fixing Solution
• 40% (v/v) Ethanol
• 10% (v/v) acetic acid
Washing Buffer
• 30% (v/v) ethanol
Sensitizing solution
• 0.02% (w/v) sodiumthiosulfate
Silver Solution
• 0.1% (w/v) silvernitrate
Developer
• 0.05% (v/v) formaldehyde
• 2% (w/v) sodiumcarbonate
Stop solution
• 5% acetic acid
Storing Solution
• 1% acetic acid
Silver Staining detecting amounts of proteins in a a range of 5-30 ng is more sensi-
tive than the Coomassie Staining but also more time-consuming. Silver ions form
complexes with the amino acids glutamate, aspartate and cysteine, then the ions get
reduced by formaldehyde to the elemental silver form. As also lipids and nucleic
acids are stainable, specificity of Silver Staining is reduced. After the SDS-PAGE the
gel was incubated in Fixing Solution for 20-30’ followed by two cycles of washing in
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washing solution for 20’ each. Then the gel was rinsed 3x in ddH2O 1’ each and then
incubated in ddH2O for 20’ under gentle agitation. Subsequently the gel was sensi-
bilized for 1-2’ in sensitizing solution then immediately rinsed 4x for a few seconds
in ddH2O and afterwards incubated in Silver Solution for 30’ at 4◦C. After a final
washing step of 30” in ddH2O the gel was incubated in developer until an appropri-
ate signal intensity compared to background was reached. Developing reaction was
interrupted by warping the developer and incubation of the gel in Stop Solution. The
gel was stored in Storing Solution.
4.8.9 Western Blot
Semi-dry Transfer Buffer
• 25 mM Tris base
• 192 mM glycine
• 20% (v/v) methanol
0.2% (w/v) Ponceau S in 3% (v/v) TCA
The Western Blot was essentially performed according to Towbin (Towbin et al.,
1979). Proteins separated by SDS-PAGE can be transferred electrophoretically onto
nitrocellulose. The transfer is specific to the proteins and leads to removal of the SDS
which causes, at least partially, renaturation of the proteins allowing for subsequent
immunodetection. The semi-dry transfer includes a ”sandwich” of gel and mem-
brane covered by two thin Whatman papers soaked in semi-dry transfer buffer. This
sandwich was placed in a blotting chamber between two electrode plates, carefully
avoiding air bubbles. Proteins were transferred from the gel to the membrane for 75’
at 1.5 mA per cm2 of membrane size. Ponceau S staining for 1-2’ and destaining with
two times washing in dH2O fixed the proteins and controlled transfer efficiency.
4.8.10 Immunodetection of Proteins
PBS-T
• PBS
• 0.05% (v/v) Tween-20
Blocking Buffer
• PBS-T
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• 5% (w/v) skim milk powder or BSA
ECL solutions (Pierce)
After blotting proteins onto a nitrocellulose membrane, they can be detected by
specific antibodies. Initially, unspecific binding sites on the membrane are blocked
with non-specific proteins. Subsequently, proteins of interest are recognized by spe-
cific binding of a primary antibody. A secondary antibody which is coupled to
horseradish peroxidase (HRP) recognizes the invariable part of the primary antibody.
The light signal, which is obtained by the turnover of a chemiluminescent substrate
by the HRP, gets detected by a highly sensitive camera system. Routinely, blocking
was achieved by incubation of the membrane in blocking buffer for at least 30’. The
primary antibody was incubated o/n at 4◦ C with slight agitation. The secondary
antibody was incubated for 45-60’ at ambient temperature. Prior to the incubation
with and afterwards the secondary antibody the blot was washed 3 times for 10’ with
PBS-T. The light signal was detected using a computer-assisted camera (LAS-3000,
Fuji).
4.8.11 Tandem Affinity Purification
TAP Lysis Buffer
• 50 mM Tris pH 7.5
• 150 mM NaCl
• 1 mM EDTA
• 10% (v/v) glycerol
• 1% (v/v) NP-40
• 1 mM DTT
• 100 µM sodium vanadate
• 14 µg/ml aprotinin
• 4 µM leupeptin
• 0.5 mM PMSF
TEV Buffer
• 50 mM Tris pH 7.5
• 150 mM NaCl
• 0.5 mM EDTA
• 1 mM DTT
Calmodulin Binding Buffer
• 10 mM Tris pH 7.5
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• 150 mM NaCl
• 0.2% (v/v) NP-40
• 1 mM magnesium acetate
• 2 mM CaCl2
• 1 mM imidazole
Calmodulin Wash Buffer
• 50 mM ammonium bicarbonate pH 8.0
• 75 mM NaCl
• 1 mM magnesium acetate
• 1 mM imidazole
• 2 mM calcium chloride
Calmodulin Elution Buffer
• 50 mM ammonium bicarbonate pH 8.0
• 25 mM EGTA
IgG affinity matrix: IgG Sepharose 6 Fast Flow (Amersham Biosciences)
Calmodulin affinity matrix: Calmodulin Sepharose 4B (Amersham Biosciences)
Tandem affinity purification (TAP) allows a highly selective purification of proteins
and protein complexes under native conditions. Two different tags on the protein
grant a high purity of the protein of interest. Two successive purification steps are
employed: the first one involves the binding of Protein A to IgG Sepharose beads. The
purified proteins are eluted from the beads through cleavage of the Protein A-tag by
TEV protease. The second step is the binding of the second tag, the residual Calmod-
ulin binding peptide, to Calmodulin Sepharose beads. To elute the proteins from this
step EGTA is used. EGTA disrupts the Ca2+-dependent binding to the Calmodulin
column.
Expression of TAP fusion proteins from stable cell lines was induced by 1 µg/ml
doxycycline for 10-14 hours. Cells were harvested by centrifugation at 200xg with
subsequent washing in PBS.
All purification steps took place at 4◦ C. The pellet was lysed in 15 ml lysis buffer
per 500 ml of suspension culture for 30’ with occasional agitation. Centrifugation
at 20,000xg for 20’ cleared the lysates from cell debris. The supernatant was incu-
bated with 125 µl equilibrated IgG Sepharose 6FF (Amersham Biosciences) per 15 ml
lysate for 1h on a tube rotator. Beads were washed three times with 1ml TEV buffer.
Beads were re-suspended in five volumes of TEV buffer. Approximately 200-500 ng
of His tagged TEV protease per 10 µl beads were added and incubated for 2 hours
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under rapid shaking. Subsequently, the beads were pelleted and the supernatant was
transferred to a new tube containing a volume equal to the volume of IgG sepharose
of equilibrated Calmodulin Sepharose 4B (Amersham Biosciences). IgG Sepharose
was washed once with three volumes of calmodulin binding buffer, pelleted and the
supernatant added to the supernatant of the TEV cleavage. After addition of 1/200
volume of 1 M CaCl2, the pooled supernatants were incubated with the Calmodulin
Sepharose for 90’.
Afterwards the pelleted beads were washed three times with calmodulin wash buffer.
After re-suspension in two volumes of elution buffer the beads were incubated for 20’
under permanent agitation. Beads were pelleted and the supernatant containing the
purified proteins was transferred to a new tube avoiding transfer of beads and stored
at -80◦ C. 25 mM MgCl2 was added prior to storage. Before usage the enzyme activity
was tested.
4.9 Enzymatic Assays
4.9.1 PARP Assay
PARP Reaction Buffer
• 50 mM Tris pH 8.0
• 0.2 mM DTT
• 4 mM MgCl2
32P-NAD+ 5 µCi/µl (PerkinElmer)
β-NAD+ (Sigma)
A PARP assay detects the incorporation of radioactive labeled 32P-NAD+ into sub-
strate proteins mediated by enzymes of the ADP-ribosyltransferase class. PARP as-
says were performed in 30 µl reaction volume at 30◦ C for 30’ in PARP reaction buffer
using 50 µM β-NAD+(Sigma) and 5 µCi 32P-NAD (PerkinElmer). Routinely 500 ng of
enzyme were used. The reactions were stopped by addition of SDS sample or RIPA
buffer. The incorporation of a radioactive label was either measured by autoradiog-
raphy or by Cerenkov counting.
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4.9.2 Protein Array
PathTM Protein Microarray Slides (Gentel)
Glass cover slips, 24x60 mm (VWR)
C-TAP PARP10
Printing Buffer (Gentel)
Blocking Buffer (Gentel)
PARP reaction buffer (see PARP Assay)
RIPA buffer (see Preparation of Whole Cell Lysates)
32P-NAD+ 5 µCi/µl (PerkinElmer)
βNAD+ (Sigma)
Super RX Medical X-Ray Film (Fuji)
0.25 µl of the samples prepared with Printing Buffer were spotted with a Nano Pipette
(Eppendorf) onto the Gentel slides. Before blocking the slides in Gentel Blocking
Buffer for 1h with gentle shaking the spots were allowed to dry for 1h. All steps were
carried out at 4◦ C.
4.9.2.1 32P-Method
Reagents were prepared immediately before usage and filtered through a 0,45 µm
Milipore filter. An overall volume of 120 µl was applied to one microarray slide, then
covered with a VWR glass cover slip cautiously avoiding air bubbles below the slip.
16 µCi 32P-NAD and 700 ng of C-TAP-PARP10 enzyme were used per microarray
slide. A negative control slide without enzyme was prepared. The activity of C-TAP-
PARP10 enzyme was confirmed by monitoring the automodification capability of the
enzyme in a PARP assay (see PARP Assay). The reaction took place in a hybridisa-
tion oven (Amersham pharmacia biotech) at 30◦C for 1 hour. After the heating period
slides were washed extensively in RIPA-Buffer, usually 6 times for 30 minutes. The
cover slip was removed during the first washing step by immersing the slide com-
pletely in washing buffer which causes the slip to float away. Before drying the slides
were desalted in ddH2O. Slides were subjected to autoradiography routinely o/n at
-80◦ C.
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4.9.2.2 Biotin Method
Washing Buffer 1% BSA in PBS-T
• 140 mM NaCl
• 2.6 mM KCl
• 2 mM Na2HPO4
• 1.45 mM KH2PO4
• 0.05% (v/v) Tween-20
• 1% (w/v) BSA
6-Biotin 17 NAD (Trevigen)
Streptavidin Alexa Fluor 647 Conjugate (Invitrogen)
Albumine from bovine serum, further purified Fraction V
KSI ProtoArray (Invitrogen)
The protocol of the 32P Method was followed but altered as indicated. Blocking was
carried out in Blocking Buffer. Instead of 32P-NAD the reaction mixture was supple-
mented with 25 µM bioNAD. Then the slide was incubated with Streptavidin Alex-
aFluor 1 µg/ml in BSA Washing Buffer for 90’. Prior to and after this step the slide was
washed 5x for 5’ in Washing Buffer. The slide was dried by centrifugation and then
analyzed on a microarray scanner (Typhoon). The procedure with the KSI Protoar-
ray was similar to the Gentel slides procedure. The analysis took place on microarray
scanner (Axon 4100A) and was bioinformatically evaluated with a special microarray
analyzing software (GenePix Pro 6.0). Each subarray was analyzed separately regard-
ing the background, positive controls, buffer controls and the other spotted proteins.
The software also took into account statistics: a protein was counted as a positive
hit only in case of being modified in both spots significantly above background lev-
els. Prospector, a software provided by Invitrogen, assisted the database search to
identify the spots according to their position on the screen.
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